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Breast cancer susceptibility after BRCA1/2: finding
the genes and potential practical applications
BAJ Ponder, AM Dunning, DF Easton, PDP Pharoah
Strangeways Research Laboratories, Departments of Oncology and
Public Health, University of Cambridge, UK
Breast Cancer Research 2006, 8(Suppl 2):S1 (DOI 10.1186/bcr1544)
Background Epidemiological studies have shown that only about 20%
of the familial clustering of breast cancer is explained by the known
highly penetrant mutations in BRCA1 and BCRA2. We have set out to
search for the genes for the remaining 80%. Twin studies indicate a
predominant role of shared genes rather than a shared environment;
the patterns of occurrence of breast cancer in families are consistent
with a major polygenic component.
Methods We have assembled a population based set of 5,000 breast
cancer cases and 5,000 controls from the East Anglian population. We
have simple clinical and epidemiological information, including family
history, and samples of blood and paraffin embedded tumour.
We have used association studies based on single nucleotide
polymorphisms, first with candidate genes and then in a genome-wide
scan of 266,000 single nucleotide polymorphisms, to search for the
putative predisposing genes. We have as yet searched only for
common variants (frequency >5%).
Results We have modelled the effects of polygenic predisposition in
the East Anglian population, and have shown that the model predicts a
wide distribution of individual risk in the population, such that half of all
breast cancers may occur in the 12% of women at greatest risk.
Both the candidate gene-based and genome-wide scans have provided
provisional identification of a number of novel susceptibility genes, and
these are currently being confirmed by a world-wide consortium of
independent laboratories totalling 20,000-plus cases and controls. No
single gene so far identified contributes more than 2% of the total
inherited component, consistent with a model in which susceptibility is
the result of a large number of individually small genetic effects.
S2
Translating breast cancer research into clinical
practice – new approaches and better outcomes
SRD Johnston
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Evolution of aromatase inhibitors as an endocrine
treatment for breast cancer
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S4
BRCA1 transcriptionally regulates genes associated
with the basal breast cancer phenotype
JE Quinn, CR James, JJ Gorskii, PB Mullan, DP Harkin
Centre for Cancer Research and Cell Biology, Queen’s University
Belfast, Belfast City Hospital, Belfast, UK
Breast Cancer Research 2006, 8(Suppl 2):S4 (DOI 10.1186/bcr1547)
Background Ten to twenty per cent of breast tumours exhibit a basal-
like genetic profile and these tumours carry a poor prognosis. Breast
tumours which contain germline mutations for BRCA1 commonly
exhibit a molecular profile similar to basal breast tumours. BRCA1 is a
tumour suppressor gene which is mutated in up to 5–10% of breast
cancer cases and is involved in multiple cellular processes including
DNA damage control, cell cycle checkpoint control, apoptosis,
ubiquitination and transcriptional regulation.
Methods  Microarray-based profiling was carried out using the
HCC1937EV and HCC1937BR breast cancer cell lines. Basal gene
and protein expression levels were analysed by qRT-PCR and western
blotting. ChIP analyses were performed and demonstrated that BRCA1
regulates basal gene expression through a transcriptional mechanism
involving c-myc.
Results We have previously carried out microarray-based expression
profiling to examine differences in gene expression when BRCA1 is
reconstituted in BRCA1 mutated HCC1937 breast cancer cells. We
observed that p-cadherin and the cytokeratin 5 and cytokeratin 17
genes, which are strongly correlated with the basal phenotype, are
differentially expressed when BRCA1 is reconstituted. In addition,
qRT-PCR and ChIP analysis of BRCA1 reconstituted cells show that
BRCA1 represses the expression of these basal genes by a
transcriptional mechanism. Furthermore, abrogation of endogenous
BRCA1 protein in the T47D cell line using siRNA results in re-
expression of these basal genes, suggesting that BRCA1 expression
levels may be important in basal gene expression.
We have also demonstrated that BRCA1 is physically associated with
the promoter regions of basal genes through an association with
c-myc. Consequently, we have confirmed that siRNA inhibition of c-myc
in T47D cells results in re-expression of these genes.
Conclusions  Our results suggest that BRCA1 is involved in the
transcriptional regulation of genes associated with the basal phenotype
and that BRCA1 controls basal gene expression through a
transcriptional mechanism involving c-myc. Further work is now
concentrating on defining the relationship between BRCA1 and basal
gene expression and how this may affect clinical responses to breast
cancer chemotherapy.
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Regulation of recombinational repair by the familial
breast cancer susceptibility protein BRCA2
SC West, F Esashi
Cancer Research UK, London Research Institute, South Mimms, UK
Breast Cancer Research 2006, 8(Suppl 2):S5 (DOI 10.1186/bcr1548)
Background  Inherited mutations in BRCA2 are associated with a
predisposition to early-onset breast cancers. The underlying basis of
tumourigenesis is thought to be linked to defects in DNA double-strand
break repair by homologous recombination (HR), as indicated by the
spontaneous chromosomal instability phenotype of BRCA2-defective
cell lines. The BRCA2 protein interacts with ssDNA and the RAD51
recombination protein, and is proposed to recruit RAD51 to the
damage site for the HR repair.
Methods Recombinant BRCA2 fragments that cover the entire length
of BRCA2 were tested for interaction with RAD51 and for their
phosphorylation using cell free extracts. An antibody that specifically
recognises BRCA2 phosphorylated at serine 3291 was generated and
used to analyse the phosphorylation status of endogenous BRCA2
during the cell cycle and after DNA damaging treatment. A cell line that
stably expresses a C-terminal BRCA2 fragment was generated, to
allow the analysis of RAD51 interactions and ability to promote
homologous recombinational repair (HRR).
Results We found that the C-terminal region of BRCA2, which directly
interacts with RAD51, contains a site (S3291) that is phosphorylated
by cyclin-dependent kinases. Phosphorylation of S3291 increases as
cells progress towards mitosis, and was shown to block C-terminal
interactions between BRCA2 and RAD51. However, DNA damage
overcomes cell cycle regulation by reducing S3291 phosphorylation
and stimulating interactions with RAD51. HRR is defective in cells
overexpressing the C-terminal fragment of BRCA2, indicating that
interactions between RAD51 and the C-terminal region of endogenous
BRCA2 are important for repair.
Conclusion  We suggest that S3291 phosphorylation provides a
molecular switch that can regulate RAD51-mediated HRR. Loss of
phosphorylation in response to DNA damage allows interactions
between RAD51 and the C-terminal region of BRCA2 and may
facilitate the loading of RAD51 on damaged DNA [1]. Importantly, a
S3291 nonphosphorylatable mutation (P3292L) has been found in
familial breast cancer patients, implicating a role of S3291
phosphorylation in the maintenance of genome integrity.
Acknowledgements This research was supported by Breast Cancer
Campaign (SCW), Cancer Research UK (SCW, FE), the Human
Frontiers Science Program (FE) and the Japan Society for the
Promotion of Science (FE).
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Chromosome translocations may play a significant
role in breast cancer
KL Howarth1, KA Blood1, JC Pole1, SL Cooke1, Y-L Chua1, 
JC Beavis1, B-L Ng2, PAW Edwards1
1Hutchison-MRC Research Centre, University of Cambridge, UK;
2Sanger Institute, Hinxton, UK
Breast Cancer Research 2006, 8(Suppl 2):S6 (DOI 10.1186/bcr1549)
Chromosome translocations that form fusion transcripts and/or activate
expression of genes by promoter insertion are key events in leukaemias
and lymphomas, and mesenchymal tumours, but it has been
fashionable to think they are irrelevant to the common epithelial
cancers such as breast cancer. However, that view is now being
challenged [1-4]; in particular, we have shown that NRG1 is
translocated in breast cancers [3]. It seems likely that some
translocations in breast cancers target specific genes at their
breakpoints, and this is particularly likely for reciprocal translocations.
We are cataloguing translocation breakpoints in breast cancer cell
lines and tumours. We use array painting, in which individual
chromosomes are purified in a cell sorter and their DNA hybridized to
microarrays. We have analysed all the chromosomes of three breast
cancer lines to 1 Mb resolution or better.
A striking finding was that reciprocal and more complex balanced
translocations are far more frequent than expected. Together the three
lines had at least 14 balanced translocations, almost three times more
than identified by cytogenetics – the cryptic ones involved small
fragments, or were obscured by subsequent rearrangement. Further-
more, several translocation breaks were in genes, including known
cancer-critical genes such as EP300/p300 and CTCF. This supports
the emerging idea that chromosome rearrangement plays a major role
in the gene changes that cause breast cancer.
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Regulation of human breast stem cells
RB Clarke
Breast Biology Group, Division of Cancer Studies, University of
Manchester, Paterson Institute for Cancer Research, Manchester, UK
Breast Cancer Research 2006, 8(Suppl 2):S7 (DOI 10.1186/bcr1550)
Breast epithelial stem cells are thought to be the primary targets in the
etiology of breast cancer. Since breast cancers mostly express
estrogen receptor-alpha (ERα), we examined the biology of these cells
and their relationship to stem cells in normal human breast epithelium.
We employed several complementary approaches to identify putative
stem cell markers, to characterise an isolated stem cell population and
to relate these to cells expressing ERα. ERα-positive cells were found
to coexpress the putative stem cell markers p21CIP1 and Msi-1. Human
breast epithelial cells with Hoechst dye-effluxing ‘side population’ (SP)
properties characteristic of mammary stem cells in mice were
demonstrated to be undifferentiated cells by lack of expression of
myoepithelial and luminal epithelial membrane markers. These SP cells
were sixfold enriched for ERα-positive cells and expressed several-fold
higher levels of the ERα, p21CIP1 and Msi1 genes than non-SP cells. In
contrast to non-SP cells, SP cells formed branching structures in
matrigel which included cells of both luminal and myoepithelial
lineages. The data suggest a model where scattered ERα-positive cells
are stem cells that self-renew through asymmetric cell division and
generate patches of transit amplifying and differentiated cells.
In recent studies we have been investigating breast cancers for the
presence of a stem cell population. Using a nonadherent culture
method analogous to neurosphere culture that enriches for neural stem
cells, we have demonstrated that breast cancer cell lines and primary
tumours contain a self-renewing population that is highly regulated by
the Notch receptor signaling pathway. Inhibitors of this pathway could
represent a new therapeutic modality in breast cancer, perhaps
through combination with current treatments.
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we have applied functional genomics using an RNAi library targeting
~8,000 genes involved in cancer. This has revealed the importance of
several pathways not previously associated with stem cell self-renewal.
These pathways may represent novel targets for breast cancer therapy
aimed at the breast cancer stem cells that survive conventional
therapies.
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Aberrant activation of Notch signalling in human
breast cancer
S Stylianou1, GM Collu1, RB Clarke2, K Brennan1
1Wellcome Trust Centre for Cell Matrix Research, Faculty of Life
Sciences, University of Manchester, Manchester, UK; 2Cancer
Research UK Department of Medical Oncology, University of
Manchester, Christie Hospital NHS Trust, Manchester, UK
Breast Cancer Research 2006, 8(Suppl 2):S8 (DOI 10.1186/bcr1551)
Background Like many developmental signalling pathways, the Notch
pathway has been linked to the aetiology of several different human
cancers. The development of focal adenocarcinomas in the murine
mammary gland [1] and the transformation of both normal murine and
human breast epithelial cell lines following Notch activation [1,2] have
long suggested that the pathway may play a role in human breast
cancer. However, this question has received little attention.
Methods Activation of the Notch pathway in human breast cancer cell
lines and breast carcinoma samples was monitored by western blotting
with an antibody that recognises the cleaved Notch1 intracellular
domain which is produced during signalling. Regulation of apoptosis by
Notch was studied in MCF 10A cells transformed by overexpressing
the Notch1 intracellular domain. Apoptosis was triggered by treating
cells with the kinase inhibitor staurosporine or the DNA damaging
agents melphalan and mitoxantrone, and monitored by nuclear
fragmentation or cleavage of caspase 3. Changes in the apoptotic
machinery were examined by western blotting using a range of
antibodies that recognise both total and phosphospecific forms of
different components.
Results  We will present data showing that Notch signalling is
activated in a wide range of breast cancer cell lines and in a panel of
20 human breast carcinomas of different pathological grade and
prognosis. In addition, we will demonstrate that sustained signalling is
required to maintain the transformed phenotype of breast cancer cell
lines, as its inhibition by expressing Numb, a natural inhibitor of the
pathway, causes both MCF7 and MDA-MB-231 cells to adopt a
normal phenotype. Our data with the normal breast epithelial cell line
MCF 10A indicate that Notch signalling contributes to the transformed
phenotype by inhibiting apoptosis. Activation of Notch signalling in
these cells by overexpressing the Notch1 intracellular domain prevents
apoptosis in response to growth factor withdrawal, removal from the
extracellular matrix and DNA damage. Finally, we will provide evidence
that the apoptosis resistance seen in Notch transformed MCF 10A
cells is through the activation of the Akt survival pathway.
Conclusion Altogether this suggests that targeting Notch signalling
may be a novel therapeutic strategy for the treatment of breast cancer.
Acknowledgements  This work was supported by Breast Cancer
Campaign. KB was a Wellcome Trust Research Career Development
Fellow.
References
1. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G,
Callahan R: Expression of an activated Notch-related int3
transgene interfers with cell differentiation and induces neo-
plastic transformation in mammary and salivary glands. Genes
Dev 1992, 6:345-355.
2. Dievart A, Beaulieu N, Jolicoeur P: Notch1 in the development
of mouse mammary tumours. Oncogene 1999, 18:5973-5981.
S9
Novel roles for integrins in tumour angiogenesis
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cellulaire, Illkirch Cedex, CU de Strasbourg, France
Breast Cancer Research 2006, 8(Suppl 2):S9 (DOI 10.1186/bcr1552)
The laminin receptors α3β1 and  α6β1 are expressed by endothelial
cells, but their direct roles in tumour angiogenesis and especially
breast cancer angiogenesis remains unexplored. We show that α6β1-
integrin is expressed in 80–90% of blood vessels associated with
normal breast or ductal carcinoma in situ. However, the proportion of
vessels that express α6β1 drops to less than 30% in invasive ductal
carcinoma samples, suggesting that loss of this laminin receptor can
enhance invasive carcinoma angiogenic events. Furthermore, the
deletion of α6-integrin or α3-integrin in ex vivo angiogenic assays can
promote VEGF-mediated microvessel sprouting. Taken together these
results implicate these integrins in the negative control of angiogenesis.
Since global deletion of the α3-integrin or α6-integrin genes in mice is
lethal, we have generated mice where these genes are deleted on
endothelial cells only.
Our data indicate that mice deficient in individual laminin receptors on
endothelial cells in vivo not only support tumour growth but have
enhanced tumourigenesis. Moreover, tumour angiogenesis is elevated
in these mice, suggesting strongly that laminin receptors are not
required for tumour angiogenesis. We also observed that angiogenic
responses to hypoxia are enhanced in mice deficient for laminin
receptors on endothelial cells and have evidence that, at least in α3-null
endothelial cells, VEGF-receptor 2 (FLK1) levels are elevated when
compared with controls. We provide the first evidence that α3-integrin
and  α6-integrin can be differentially expressed in the angiogenic
vessels associated with invasive carcinoma of the breast and suggest
that these laminin receptors can negatively regulate angiogenesis in
vivo and ex vivo.
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Genome-wide RNAi to identify genes that confer
synthetic lethality with BRCA1
MIR Petalcorin, JS Martin, SJ Boulton
Cancer Research UK, South Mimms, UK
Breast Cancer Research 2006, 8(Suppl 2):S10 (DOI 10.1186/bcr1553)
We have previously demonstrated that a functional orthologue of the
breast cancer tumour suppressor gene BRCA1 exists in C. elegans
(brc-1). Deletion mutants in C. elegans brc-1 or its heterodimeric
partner, brd-1, share many of the phenotypic hallmarks of BRCA1-
deficient human cells, yet are homozygous viable thus permitting
extensive reverse genetic analysis. Using a rapid and inexpensive
genome-wide screen in C. elegans we set out to identify genes that
could be targeted in human patients to selectively kill tumours defective
in the BRCA pathway. To this end we have utilized the complete C.
elegans RNA-mediated interference library to systematically inactivate
all 19,500 C. elegans genes and have identified those genes whose
depletion confers synthetic lethality in combination with brc-1 and brd-
1 mutations. In total, this screen identified 20 genes including pme-1
and pme-2, the C. elegans counterparts of PARP, a gene whose
inhibition selectively kills BRCA defective tumour cells. We are
currently using siRNA to knockdown all human homologues to identify
those genes whose inactivation specifically kills mammalian cells
harbouring mutations in BRCA1. These results and our current
progress will be presented.
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Microarray studies reveal novel genes associated
with endocrine resistance in breast cancer
RS Burmi1, RA McClelland1, D Barrow1, IO Ellis2, 
JFR Robertson2, RI Nicholson1, JMW Gee1
1Tenovus Centre for Cancer Research, Welsh School of Pharmacy,
Cardiff University, Cardiff, UK; 2Department of Histopathology &
Professorial Unit of Surgery, City Hospital, Nottingham, UK
Breast Cancer Research 2006, 8(Suppl 2):S11 (DOI 10.1186/bcr1554)
Background Endocrine resistance is a major hurdle in breast cancer
management, and determining the underlying factors driving its growth
and aggressive behaviour should vastly improve treatment.
Methods  Microarray technology (BD Atlas Plastic Human 12K
Microarrays; GeneSifter software), verified by PCR, western blotting
and immunocytochemisty, was used to identify genes increased in
acquired resistant models to tamoxifen (TamR) or faslodex (FasR) as
potential predictive/prognostic markers and new therapeutic targets.
Results  Alongside known breast cancer genes (β-catenin, PEA3,
vitronectin, CD44), two novel genes in endocrine resistance were
revealed (the latter never previously described in breast cancer): a
securin/cell cycle regulator Pituitary Tumour Transforming Gene-1
(PTTG1), and GDNF receptor-alpha 3 (GFRα3) reported to promote
cell survival signalling via RET coreceptor. Altered levels of PTTG1,
GFRα3, or their associated family members were observed in further
endocrine resistant states, including an additional faslodex resistant
model that has progressed to a highly-aggressive state (FasR-Lt) and
XMCF-7 cells resistant to oestrogen deprivation. PTTG1 and GFRα3
induction were also implicated in limiting response to anti-EGFR
agents currently in breast cancer trials, with GFRα3 ligand (artemin)
largely overcoming drug response. mRNA studies in clinical disease
revealed PTTG1 associated with lymph node spread, high tumour
grade and proliferation, while GFRα3 was enriched in ER-negative
tumours and those expressing EGFR, profiles implying roles in clinical
resistance and aggressive tumour behaviour. Promisingly, PTTG1 or
GFRα3 siRNA knockdown promoted cell kill and inhibited proliferation
in the resistant models.
Conclusion Cumulatively, these data indicate PTTG1 and GFRα3 may
provide useful biomarkers, and perhaps clinically relevant therapeutic
targets for multiple resistant states.
Acknowledgement  Funding from Breast Cancer Campaign is
gratefully acknowledged.
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Benefits of combined treatments using antiresorptive
agents and cytotoxic drugs
I Holen, H Neville-Webbe, RE Coleman
DU39, School of Medicine and Biomedical Sciences, University of
Sheffield, Sheffield, UK
Breast Cancer Research 2006, 8(Suppl 2):S12 (DOI 10.1186/bcr1555)
Background  Breast cancer patients often receive a combination of
different therapies, but our understanding of how best to utilise such
combinations to achieve maximal benefit for the patients is incomplete.
We have investigated the ability of the antiresorptive agent zoledronic
acid (Zol) and the commonly used chemotherapy agents paclitaxel
(Pac) and doxorubicin (Dox) to induce apoptotic breast cancer cell
death in vitro.
Methods  Hormone-dependent (MCF7) and hormone-independent
(MDA-MB-436) breast cancer cells were treated with increasing doses
of Zol, alone and in sequence or combination with a low dose of Pac
(2 nM) or Dox (0.05 µM) for 1–72 hours. The following treatment
groups were used: (A) untreated controls, (B) each drug given as a
single agent, (C) the drugs given simultaneously, (D) chemotherapy
agent followed by Zol, and (E) Zol followed by the chemotherapy agent.
In some cases Zol was given together with GGOH, a downstream
component of the mevalonate pathway targeted by Zol. The effects of
the different treatments on both apoptotic and necrotic cell death were
determined at 72 hours, by evaluation of nuclear morphology following
staining with Hoechst and PI. The effects of the various treatments on
the cell cycle distribution were also determined.
Results  Our data show that exposing breast cancer cells to the
chemotherapy agent prior to Zol results in a synergistic increase in
tumour cell death, compared with when the drugs are used as single
agents. This was seen both for paclitaxel and doxorubicin, and the
effect was found to be associated with changes in the cell cycle
distribution following pretreatment with the cytotoxic drug. The
synergistic increase in tumour cell death could be reversed by addition
of GGOH, a compound that counteracts the effects of Zol on a key
metabolic pathway, supporting an essential role of Zol in the toxic
effects of the combined treatments. We also show that these effects
are significant using clinically achievable doses and exposure times,
suggesting that sequential treatments may be relevant also in a clinical
setting.
Conclusions We have shown that combining chemotherapy agents
and the antiresorptive drug Zol results in a synergistic increase in
breast cancer cell death in vitro. We are currently investigating whether
the same is seen using more complex in vivo model systems. Our data
suggest that in order to achieve maximum benefit from combined
treatments, the order and timing of the combinations are crucial.
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Loss of C-terminal binding protein transcriptional
corepressor leads to aberrant mitosis and cell death
in breast cancer cells
L Bergman, J Blaydes
University of Southampton, Southampton General Hospital,
Southampton, UK
Breast Cancer Research 2006, 8(Suppl 2):P1 (DOI 10.1186/bcr1556)
C-terminal binding proteins (CtBPs) are transcriptional corepressors
that regulate the activity of proteins important for a wide variety of
cellular processes, including development, proliferation, differentiation,
and transformation. Many targets of CtBP corepression are members
of pathways involved in tumorigenesis, and evidence is emerging that
CtBPs also play a role in cell survival. Loss of CtBP in different
experimental systems leads to upregulated expression of a number of
proapoptotic genes and increased sensitivity to apoptosis.
In this study, we have continued investigation into the role of CtBPs in
breast cancer cell survival, identifying a previously unknown function for
CtBPs in the regulation of the mitotic spindle checkpoint. Loss of CtBP
expression by RNAi results in a marked decrease in cell number, and in
reduced cell viability and clonogenicity. We find that this apparent cell
death does not occur by a traditional caspase-mediated apoptotic
pathway.
Detailed microscopic analysis of the morphology of MCF7 breast
cancer cells lacking CtBPs reveals an increase in the number of cells
containing abnormal micronucleated cells and dividing cells with
lagging chromosomes, indicative of aberrant mitotic chromosomal
segregation. Live cell imaging reveals defects in cell abcission after
mitosis following CtBP knockdown. Furthermore, cells lacking CtBP fail
to undergo mitotic arrest induced by spindle toxins, indicating a spindle
checkpoint defect. The loss of cell viability in breast cancer cells
following CtBP inhibition is most probably a consequence of aberrant
mitosis and cell death by mitotic catastrophe. Here we present a
detailed characterization of the mechanism by which CtBPs are
involved in mitosis and cell survival, which we hope will increase our
understanding of how breast cancer cells evade cell death, and
ultimately lead to new treatments for patients.
Acknowledgement  This research was funded by Breast Cancer
Campaign.
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Phenotypic characterization of mouse mammary
epithelial stem and progenitor cells
J Stingl1,2, CJ Eaves2, CJ Watson1
1Department of Pathology, University of Cambridge, Cambridge, UK;
2Terry Fox Laboratory, British Columbia Cancer Research Centre,
Vancouver, Canada
Breast Cancer Research 2006, 8(Suppl 2):P2 (DOI 10.1186/bcr1557)
Elucidation of the genes controlling the proliferation and differentiation
of mouse mammary epithelial stem (MaSC) and progenitor (Ma-CFC)
cells is paramount to understanding the processes that regulate
mammary gland development and breast cancer progression. We have
previously described a strategy in which MaSC and Ma-CFC can be
purified to 5% and 15%, respectively, on the basis of lack of
expression of the hematopoietic and endothelial markers CD45,
Ter119 and CD31 and on the differential expression of CD24 and
CD49f [1], with the MaSC having a CD24medCD49fhigh phenotype and
the Ma-CFC having a CD24highCD49flow phenotype. Currently, a
definitive analysis of the gene expression profiles of MaSC and
Ma-CFC is not possible due to the presence of large numbers of
contaminating cells in these enriched subpopulations. However, a
preliminary microarray analysis of these subpopulations has identified
potential new cell surface markers that can be exploited to further
purify MaSC and Ma-CFC. We have initiated a screening program
using the markers identified in the microarray analysis as well as
markers used to identify other adult tissue stem cells to further purify
and characterize MaSC and Ma-CFCs. Results of this screen will be
presented.
Acknowledgement  This work is supported by Breast Cancer
Campaign.
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Characterisation of the tumour suppressor gene ZAC
in breast tissue
EM Valleley, SF Cordery, M Shires, V Speirs, DT Bonthron
Leeds Institute of Molecular Medicine, University of Leeds, St James’s
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Breast Cancer Research 2006, 8(Suppl 2):P3 (DOI 10.1186/bcr1558)
ZAC (also known as PLAGL1/LOT1) is a transcription factor gene
located on chromosome 6q24, a region that is frequently deleted in
solid tumours. ZAC is known to promote cell cycle arrest and
apoptosis, and loss of expression has been observed in several
different cancers including primary breast tumours and breast cancer
cell lines. Due to its antiproliferative properties, the downregulation or
loss of this gene would be expected to deregulate cell growth. ZAC
has also been shown to act as a transcriptional coactivator of nuclear
receptors, including oestrogen receptors which are important as
prognostic indicators and therapeutic targets in breast cancer.
ZAC is maternally imprinted in most tissues. Its promoter is believed to
be located within a differentially methylated CpG island, and it directs
transcription exclusively from the unmethylated paternal allele. As this
imprinted promoter has been shown to be hypermethylated in ovarian
cancer and breast cancer cell lines, similar epigenetic changes may
occur in primary breast tumours, and may contribute to altered cell
cycle regulation and thus tumour growth. In some tissues, however,
ZAC expression is biallelic. We are currently studying the mechanism
underlying this tissue-specific phenomenon. A detailed understanding
of the way in which the expression of imprinted and nonimprinted
transcripts is regulated in normal breast tissue will be required in order
to allow analysis of the epigenetic mechanism for ZAC inactivation in
breast tumours.
Acknowledgements This study is funded by Breast Cancer Campaign
and The West Riding Medical Research Trust.
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Role of BRCT motif containing proteins in Chk1
activation
RG Beniston, CGW Smythe
University of Sheffield, Sheffield, UK
Breast Cancer Research 2006, 8(Suppl 2):P4 (DOI 10.1186/bcr1559)
Introduction  Chk1, along with Chk2, regulates processes such as
DNA replication, cell cycle control, chromatin restructuring and
apoptosis. DNA damage/replication stress activates Chk1 by
phosphorylation from the PI3/PI4 family of kinases. Activation of Chk1
is thought to be mediated by proteins containing the BRCA1 C-
terminal domain (BRCT). We previously identified a potential complex
of four Chk1-associated proteins by immunoprecipitation, western
blotting and mass spectrometry, one of which is BRCA1. Germline
mutations in BRCA1 are responsible for many cases of hereditary
breast cancer, and cells deficient in BRCA1 sustain spontaneous
aberrations in chromosome structure. Such findings indicate that
BRCA1 is essential for suppressing genome instability.
Method and results Studies have concentrated on the role of BRCA1,
with other BRCT-motif proteins, in the regulation of Chk1. Through
immunoprecipitation assays and analysis of the phosphorylation status
of Chk1, in both wildtype and mutated BRCA1 cell lines, we have
shown that although BRCA1 forms a complex with Chk1, it is not
essential for the activation of Chk1 in response to either stalled
replication forks (induced by hydroxyurea) or double-stranded DNA
breaks (induced by ionising radiation). In contrast, we have observed
that the loss of both BRCA1 and the knockdown of the fission yeast
rad4/Cut5 related protein Topisomerase II binding protein 1 (TopBP1)
inhibit activation in response to DNA damage but not stalled replication
forks (Figure 1). However, the knockdown of TopBP1 alone was
insufficient to inhibit activation.
Conclusion  Inhibition of Chk1 activation in response to ionising
radiation requires the loss of both TopBP1 and BRCA1, suggesting
redundancy. In addition, as the response to hydroxyurea, or UV, was
unaffected, it seems likely that different proteins are involved in Chk1
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Figure 1 (abstract P4)
Loss of Topisomerase II binding protein 1 (TopBP1) and BRCA1
inhibits Chk1 activation after ionising radiation.activation in response to differing stimuli. Analysis of other Chk1
binding proteins continues determining whether they are involved in
Chk1 activation in response to stalled replication forks and/or double-
stranded DNA breaks. As Chk1 is involved in maintaining tumor cell
viability following activation of the replication checkpoint, the Chk1-
regulated checkpoint(s) may protect cells from ionizing radiation-
induced killing. The ability to delineate the control mechanisms of Chk1
is of critical importance in order to target Chk1 with the aim of
increasing the selectivity and specificity of anticancer drug treatments.
Acknowledgement Breast Cancer Campaign funded the project.
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Cambridge, UK
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Background  It has long been suspected that there is a tumour
suppressor gene on chromosome 8p, and our array CGH data [1]
suggest that it may be close to the WRN and NEUREGULIN1 (NRG1)
genes. NRG1 encodes growth factors that function as ligands for the
tyrosine kinases ErbB3 and ErbB4, and can both stimulate cell
proliferation, differentiation and apoptosis. We previously showed that
many breast carcinoma (that is, 39% of cancer cell lines and 6% of
breast tumours) have chromosome breakpoints in NRG1, suggesting
that the gene plays an important role in tumourigenesis [2,3], and our
initial hypothesis was that the translocations activate expression.
Results Our current work shows that NRG1 expression is silenced in
many breast cancer cell lines (17 out of 23 lines), as compared with
normal breast cell lines. Western blotting experiments also indicate that
NRG1 is downregulated at the protein level. To investigate whether
NRG1 maybe repressed by epigenetic mechanisms, we examined
DNA methylation at a CpG island present in the promoter and the first
exon of the gene using bisulphite sequencing. This region is heavily
methylated in 76.5% (13/17) of breast cancer cell lines that have no
NRG1 expression. In contrast, the region is relatively unmethylated in
normal breast lines, and in cancer cell lines expressing NRG1.
Treatment of cancer cell lines with 5-aza-2-deoxycytidine, which
abolished DNA methylation, activated the expression of NRG1 by
7–100 times.
Conclusion  These results suggest that DNA methylation is a key
mechanism that silences NRG1 expression in breast cancer cells, and
our current view is that NRG1 could be the long-sought tumour
suppressor on 8p, with the translocations either inactivating the gene
or producing aberrant transcripts.
Acknowledgement The authors thank Breast Cancer Campaign for
funding.
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hCLK2 couples FANCD2 to stalled replication forks
and functions in the mammalian S-phase checkpoint
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Background  Recent work has highlighted interplay between
components of the Fanconi anemia (FA) pathway, an inherited genome
instability syndrome characterized by hypersensitivity to DNA
interstrand cross-links (ICLs), and the breast cancer susceptibility
proteins BRCA1 and BRCA2/FANCD1. Is has also been suggested
that certain defects within FANCD2, which is the central factor in the
FA pathway, may lead to an increased risk of sporadic breast cancer.
Methods Mass spectrometry and candidate western blotting analyses
were carried out on FCD-2 immunoprecipitates from untreated and
cisplatin-treated whole worm extracts.
Results  Using the nematode worm as a model system, we have
identified the circadian protein CLK-2 and ATL-1 (C. elegans ATR) as
factors that coimmunoprecipitate with C. elegans FANCD2 (FCD-2)
following ICL damage. C. elegans atl-1 and clk-2 mutants and siRNA
depletion of human hCLK2 (KIAA00693) compromises FCD-2/
FANCD2 recruitment to blocked replication forks and confers ICL
sensitivity, a hallmark of FA. Cells deficient for hCLK2 are also
defective for damage-induced mono-ubiquitylation of FANCD2 and
exhibit radio-resistant DNA synthesis indicative of an S-phase check-
point defect. ATR activation leading to BRCA1-mediated ubiquitylation
remains intact in hCLK2 depleted cells, yet ATR-dependent phosphory-
lation of Chk1 and Claspin is severely attenuated following S-phase
insults. Finally, recruitment of the homologous recombination factor
RAD51 is also impaired in cells depleted of hCLK2, which leads to a
reduced homologous recombination frequency at sites of DNA
damage.
Conclusion  These data indicate that the novel factor hCLK2 is an
essential component of the mammalian S-phase checkpoint required to
coordinate both FA and HR-mediated repair responses following
replication stress.
P7
Poly(ADPribosyl)ation of CTCF: role in breast
tumourigenesis
F Docquier, D Farrar, I Chernukhin, E Klenova
Department of Biological Sciences, University of Essex, Colchester, UK
Breast Cancer Research 2006, 8(Suppl 2):P7 (DOI 10.1186/bcr1562)
Background CTCF is a conserved, ubiquitous and multifunctional 11
Zn finger (ZF) transcription factor with features of a tumour suppressor.
CTCF regulates transcription in diverse modes, such as promoter
activation and repression, silencing, constitutive and methylation-
dependent chromatin insulation. We have previously reported that
CTCF can be post-translationally regulated by poly(ADPribosyl)ation
and that this modification modulates the insulator function of CTCF
[1,2]. The purpose of the present study is to investigate the role of
CTCF poly(ADPribosyl)ation in normal and breast cancer cells.
Methods The following techniques have been used in this investi-
gation: western analysis, mass spectrometry, immunoprecipitation, cell
cultures, transient transfection, primary cultures from normal and
tumour tissues, cellular fractionation and laser capture microdissection.
Results Using a large panel of breast tumours and paired peripheral
tissues, we have discovered that only the poly(ADPribosyl)ated isoform
of CTCF (called CTCF180) is detected in normal breast tissues,
whereas the other isoform of CTCF (called CTCF130) only appears in
breast tumour tissues and immortalised cell lines (see Figure 1). The
identity of the poly(ADPribosyl)ated isoform of CTCF was further verified
by mass spectrometry. We are currently establishing primary cultures
from normal and tumour tissues in order to investigate whether the
appearance of CTCF130 is linked to immortalisation. The histological
type of cells containing CTCF180 and CTCF130 is being determined
by cellular fractionation and laser capture microdissection of breast
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generation of the CTCF180 can be associated with cell cycle arrest.
Conclusion This research addresses the molecular mechanisms of
breast tumourigenesis: CTCF180 and CTCF130 may regulate different
sets of genes and/or different cell functions specific for normal and
cancer cells, respectively. The loss of CTCF poly(ADPribosyl)ation
could also lead to epigenetic disturbances. Our data obtained so far
indicate that the transition from CTCF180 to CTCF130 could be a
hallmark of tumour development. We envisage the potential use of both
CTCF isoforms as biological markers for breast tumourigenesis.
Acknowledgements This work was funded by Breast Cancer
Campaign, The Medical Research Council, and The University of
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Investigating the role of Wnt signalling in
lobuloalveolar development of the mammary gland
RJ Evans, C Dale
Cardiff University, Cardiff, UK
Breast Cancer Research 2006, 8(Suppl 2):P8 (DOI 10.1186/bcr1563)
The Wnt signalling pathway regulates postnatal lobuloalveolar develop-
ment. Expression of Wnt inhibitors blocks lobuloalveolar development,
whereas expression of Wnt pathway activators induces precocious
lobular development. Wnt ligands have been suggested to operate by
regulating the proliferation and differentiation of lobuloalveolar pro-
genitor cells during pregnancy. However, the lobular developmental
switch is difficult to study using current experimental systems due to a
mammary-specific ‘Catch 22’ in which promoters such as MMTV and
WAP are only expressed after commitment to the lobular lineage. We
are therefore developing an inducible transgene expression system
which expresses Wnt regulators in all mammary epithelial cell types
prior to and during lobuloalveolar development. In addition we are
using Wnt-reporters to identify Wnt-responsive cells during these early
developmental stages and aim to use stem cell markers to further
characterise this subset of cells. Many studies support the idea that
breast cancer results from oncogenic changes to mammary stem cells.
This work should help establish the role Wnt signalling plays in the
expansion of lobular progenitor cells and investigate the effect that
switching the Wnt pathway on or off has on lobuloalveolar development.
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Inhibitor of apoptosis proteins in breast cancer
FM Foster, CH Streuli
Faculty of Life Sciences, University of Manchester, Manchester, UK
Breast Cancer Research 2006, 8(Suppl 2):P9 (DOI 10.1186/bcr1564)
Background and methods Resistance to apoptosis is a hallmark of
cancer. Decreased sensitivity to apoptosis leads to an elevated
therapeutic threshold for classical interventions such as chemotherapy
or radiotherapy. The Inhibitor of Apoptosis Proteins (IAPs) are a family
of proteins that prevent caspases from inducing apoptosis. Targeting
IAPs therefore represents a potential avenue for reducing the threshold
to apoptosis and improving therapeutic effectiveness. There are eight
human IAP family members, including XIAP, Survivin, cIAP1, cIAP2,
Livin, NAIP and Apollon. Although some studies have indicated altered
levels of Survivin and XIAP in several tumour models, no study to date
has examined the role of all members of the IAP family in cancer
progression. We aim (i) to investigate the expression of the whole
family of IAPs across a wide range breast cancer cell lines and tumour
samples at both the RNA and protein level, and (ii) to determine
whether targeting IAPs alters susceptibility to apoptosis.
Results Preliminary results confirm that the levels of Survivin and XIAP
vary across a breast cancer cell line panel. Expression of the other IAP
family members is currently being determined.
IAP expression will be correlated to the ER, PR, p53, Erb2, and EGFR
status of the cell lines and tumours, to determine whether there is a
relationship between IAP expression and prognostic indicators.
Overexpression and siRNA-induced knockdown approaches will be
used to investigate whether altering the expression of IAPs identified in
our original screen affects the apoptotic threshold in response to
various chemotherapeutic agents. This will be examined using both 2D
and 3D cell culture systems.
P10
Characterization of peptide aptamers to the Anterior
Gradient 2: a novel inhibitor of the tumour
suppressor protein p53
A Fourtouna, E Murray, L Hayward, L Pohler, T Hupp
Cancer Research UK, Western General Hospital, Edinburgh, UK
Breast Cancer Research 2006, 8(Suppl 2):P10 (DOI 10.1186/bcr1565)
Anterior Gradient-2 was identified using proteomic technologies as a
protein overexpressed in human cancers. We show here properties of
AG2 suggesting it has proto-oncogenic properties:(i) the AG2 protein
and gene are unregulated in a tamoxifen resistance panel of breast
cancer cells lines, (ii) cell lines overproducing AG2 have an elevated
clonogenic activity in vitro and also increase cell growth in a xenograft
model, (iii) AG2 protein inhibits the tumour suppressor protein p53,
and (iv) AG2 localizes to the endoplasmic reticulum, suggesting a
proto-onocogenic signalling pathway exists from endoplasmic
reticulum to the nucleus to inhibit p53.
To validate the AG2-mediated endoplasmic reticulum pathway as a
possible drug target, we developed peptide aptamers to AG2 protein
in order to determine whether the oncogenic properties of the protein
can be altered by the peptide ligand.
These studies hold promise for developing new types of drugs that can
release and reactivate the tumour suppressor p53 in breast cancers.
P11
Role of CASP8 D302H and other apoptosis gene
variants in breast cancer
SH Mistry, S Rafii, AL Shippen, G MacPherson, 
S Balasubramanian, MW Reed, A Cox
Medical School, University of Sheffield, Sheffield, UK
Breast Cancer Research 2006, 8(Suppl 2):P11 (DOI 10.1186/bcr1566)
Background It is well established that perturbations in high penetrance
genes such as BRCA1 and  BRCA2 predispose to breast cancer.
However, low penetrance genes are still under investigation. Some
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Figure 1 (abstract P7
Western blot analysis of six paired samples (1–6) of normal and
tumour tissues (a representative western blot of total 56 paired
samples is shown). Fifty micrograms of the total protein were used in
this assay. The bands of the CTCF 180 kDa and 130 kDa isoforms
were quantified and their additive values were normalized to the
corresponding values of α-Tubulin used as loading control (bottom
panel).apoptotic genes (for example, BIRC5, BCL2, DR4 and  DR5) have
been implicated, and we reported that a coding single nucleotide
polymorphism (SNP) in the caspase 8 gene (CASP8 D302H) is
associated with a reduced risk of breast cancer [1]. We hypothesise
that CASP8 and other apoptotic genes may play an important role in
breast cancer susceptibility. The objectives were to study the
functional effect of CASP8 D302H on apoptosis, and to perform a
case–control analysis of other CASP8 variants to determine their effect
on breast cancer susceptibility.
Methods  Apoptotic activity in peripheral blood lymphocytes (PBLs)
was measured using Annexin-V FITC with propidium iodide and FACs
analysis. Genotyping was conducted by TaqMan™ (ABI, UK).
Results  We detected a 68% increase in apoptosis in PBLs after
treatment with CD95 ligand (R & D Systems, UK) with anti-CD95
antibody (BioLegend, UK), and are currently optimising this assay as a
functional screening tool. We identified 50 SNPs in CASP8 by
database searching, and 15 more putative SNPs were sequenced, one
of which is novel (T51087A in exon 13). Using data from 33 SNPs with
a minor allele frequency >0.05 and various haplotype-tagging SNP
(htSNP) selection programs, results suggested that 11 htSNPs (PCA
method) need to be genotyped to adequately capture common genetic
variation within CASP8. A case–control study of these 11 htSNPs is in
progress.
Conclusion These methods will be used to address the hypothesis
that apoptotic genes are involved in breast cancer susceptibility and
treatment outcome. In the future, this research will help us understand
the role of the whole pathway and whether it will be amenable to
manipulation by targeted treatments.
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Background  The  PLU-1/JARID1B  gene, which is upregulated in
breast cancers, encodes for a 1,544-amino-acid multidomain protein
that is exclusively localised to the nucleus. The protein contains several
conserved domains, including the ARID DNA binding domain, both N
and C jumonji domains, three PHD domains and putative nuclear
localisation signals, indicating that it could regulate the transcription of
specific genes either through direct binding or through other
transcription factors [1,2].
In this study, we aim to identify the target genes regulated by PLU-1/
JARID1B and the possible mechanism of PLU-1/JARID1B-mediated
transcriptional regulation.
Methods  Co-immunolocalisation and/or co-immunoprecipitation of
PLU-1/JARID1B with HDACs were carried out using anti Myc/HisA
antibodies or an antiserum (αPLU-1-C) against PLU-1/Jarid1B after
transient transfection of Cos and MCF7 cells with expression vectors
coding for Myc or HisA tagged proteins. Direct interactions of PLU-1/
JARID1B expressed from a baculovirus with in vitro translated HDACs
were also demonstrated. In vitro mutagenesis and reporter assays
were also used. HB2 and MCF7 cells were subjected to microarray
using the Affymetrix gene chip HG-U133A after transduction with a
recombinant adenovirus or silencing the endogenous gene using a
short hairpin RNA (shRNA) expression vector (Imgenex). ChIP assays
were carried out using the αPLU-1-C specific antiserum or an antibody
against the acetylated form of Histone H3. PCR-assisted DNA binding
selection from a random pool of oligonucleotides was carried out using
in vitro translated full-length PLU-1/JARID1B and GST-PLU-1-ARID.
Results PLU-1/JARID1B binds to chromatin and the nuclear matrix and
localises in MAD bodies when co-transfected with class IIa histone
deacetylases (HDACs) or N-CoR. Direct binding to class I and class IIa
HDACs is demonstrated using co-immunoprecipitation assays and
binding of PLU-1/JARID1B to in vitro translated HDACs. Two PHD
domains in PLU-1 were shown to be crucial for binding to a domain in
the N-terminal region of HDAC4 and for the transcriptional repression.
Approximately 100 target genes were identified by microarray analysis
after overexpressing or silencing the human PLU-1/JARID1B gene in
human mammary epithelial cells using adenovirus and RNA inter-
ference systems, respectively. Most of the candidate genes were
downregulated by PLU-1/JARID1B overexpression, including the
mellathionein (MT) genes, the BRCA1 gene, and genes involved in the
regulation of the spindle and G2/M checkpoints such as BUBR1,
BUB3, STK6, TTK, CDC2 and Cyclin B1. ChIP assays confirmed that
the MT1H, MT1F and MT1X genes are direct transcriptional targets of
PLU-1/JARID1B, and that PLU-1/JARID1B affects the level of
acetylation of the promoter of the MT1H gene. Some other candidate
genes such as BRCA1 may be downregulated indirectly. The PLU-1/
JARID1B ARID domain preferentially binds to a GCACA motif, a
putative consensus sequence that is abundant in MT promoters.
Conclusion  The downregulation of the metallothionein genes,
checkpoint genes and BRCA1 by PLU-1/JARID1B overexpression is of
great interest and could be highly relevant to any role this protein plays
in the development and progression of breast cancer.
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Potential role of cyclin D1 in DNA damage response
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Breast Cancer Research 2006, 8(Suppl 2):P13 (DOI 10.1186/bcr1568)
Background In mammalian cells, cell cycle progression is governed by
distinct cyclin-dependent kinases (cdks) whose activities are regulated
by binding of their activating cyclin subunits and through negative
regulation by inhibitor proteins such as p21. Cyclin levels oscillate in a
phase-dependent manner, ensuring the stage-specific activation of
cyclin/cdk complexes. The D-type cyclin levels are thought to act as
sensors of the cellular environment: under conditions permissive for
proliferation, D-type cyclins accumulate and facilitate the G1 phase
progression; whereas under restrictive conditions, D-type cyclin
transcription is attenuated and the protein is destabilised via ubiquitin-
mediated proteolysis. In addition to the normal cell cycle regulation, a
member of D-type cyclins, cyclin D1, has been implicated in the DNA
damage response. Once activated, DNA damage responses disrupt
the function of the cell cycle and can result in a number of outcomes
including short-term or long-term cell cycle arrest, apoptosis and
necrosis. Cyclin D1 expression is often found deregulated in cancerous
cells, particularly in those of the breast and the head/neck.
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responds to the DNA damage induced by an environmental
carcinogen, 4-nitroquinoline 1-oxide (4NQO), in a biphasic manner. At
a low level (2.5 µM), the cyclin D1 level is unchanged but p21 is
induced strongly after 3 hours; at intermediate levels (10–50 µM),
there is a dramatic reduction in the level of cyclin D1 while p21 fails to
accumulate; at high levels (100–200 µM), little change in cyclin D1 or
p21 is observed. The cellular responses associated with different
4NQO doses analysed by flow cytometry will be presented.
Conclusion Our findings suggest that the level of cyclin D1 following
the DNA damage induced by 4NQO may play a role in dictating the
outcome of the cellular response. Our ongoing research aims to
compare and contrast the cellular responses linked to various specific
DNA damaging agents in terms of cell cycle regulatory proteins,
focusing on cyclin D1, and ultimately to understand the molecular
mechanisms underlying the regulation of such responses.
Acknowledgements  Linda Jacobs Breast Cancer Campaign PhD
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breast myoepithelial cells
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Background Normal breast myoepithelial cells have been shown to
exhibit tumour-suppressor activity mediated, in part, by downregulation
of MMP expression [1]. DCIS myoepithelial cells have an altered
phenotype as demonstrated by a different gene expression profile [2].
We have identified upregulation of α(v)β6 integrin on myoepithelial cells
in a subset of DCIS; however, the role of α(v)β6 in this context is not
clear.  α(v)β6 is not expressed by normal epithelial cells, but is
expressed in some cancers where it promotes tumour cell invasion and
enhances MMP expression.
Methods The purpose of this project is to investigate the hypothesis
that DCIS-associated myoepithelial cells lose their tumour suppressor
effect and acquire a tumour promoting activity. There are three general
aims: (1) to generate a series of myoepithelial cell models to mimic
DCIS-associated myoepithelial cells and overexpress α(v)β6 to assess
the contribution of this integrin; (2) to compare tumour suppressor/
promoter properties of normal, α(v)β6 overexpressing and DCIS-
associated myoepithelial cells; and (3) to examine the effect of de novo
α(v)β6 expression on the biological activity of myoepithelial cells.
Results We have fully characterised an immortalised myoepithelial cell
line, engineered it to overexpress α(v)β6 and determined that it is
functional. We are starting to examine the morphology and phenotype
of these cells to determine any differences, and we have been able to
show the parental cell line is able to recapitulate the tumour suppressor
effect in in vitro systems. We are now looking into what effect the
expression of α(v)β6 has in these systems. We are also in the process
of trying to create further myoepithelial cell lines from primary cells
isolated from patient tissue.
Conclusion  Through this work we hope to identify the role α(v)β6
expression has in DCIS myoepithelial cells with the goal of making this
integrin a viable therapeutic target in the future.
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Background In order to provide potential diagnostic markers and to
identify potential targets for breast cancer therapy, gene products that
are differentially expressed between benign and malignant cells have
been isolated and identified by a combination of PCR-selected
suppression subtractive libraries [1,2] and inhouse cDNA microarrays,
screened using mRNAs from human breast cancer specimens. A
number of the cDNAs were differentially expressed by greater than
twofold, including the one for AGR2, the secreted human homologue
of a Xenopus developmental protein.
Methods and results In an in vivo model system of metastasis, AGR2
induced metastases compared with no metastases in the control
groups [3]. In immunocytochemistry with an inhouse affinity-purified
AGR2 antiserum [3], the presence of AGR2 protein in tumour
specimens was statistically significantly associated with malignancy,
with oestrogen receptor (ER) alpha-positive carcinomas, with low
histological grade and with reduced patient survival over a 10-year
period of follow-up of a group of ER-positive cases [4].
Conclusions Our results demonstrate that AGR2 is causatively
involved in metastasis and associated with poor outcome in patients
with breast cancer, indicating that AGR2 might be a valuable new
potential diagnostic marker and possible target for breast cancer
therapy. Further studies are essential to understand the mechanism of
AGR2-induced metastasis.
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Insulin-like growth factor signalling in oestrogen
nonresponsive breast cancer cells
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Background Insulin-like growth factors (IGFs) regulate normal growth
and development. In breast cancer, they stimulate cell proliferation, cell
migration and inhibit apoptosis. The IGF signal transduction pathway is,
therefore, a potential therapeutic target in the treatment of breast
cancer [1,2]. Inhibitors of the IGF pathway may be effective in the
treatment of breast cancer with de novo or acquired endocrine
resistance. We have studied IGF signalling in oestrogen nonresponsive
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of endocrine resistant breast cancer. Oestrogen responsive MCF-7
cells were also studied.
Results Components of the IGF signalling pathway, type I IGF
Receptor (IGF1R), IRS-1, IRS-2, and the three Shc isoforms, were
expressed at varying levels, demonstrating a range of phenotypes in
the breast cancer cells. IRS-1 is expressed in a truncated form in the
BT-20 cells as an antibody to the C-terminus is unable to detect the
protein.
IGF-1 activated IGF1R, IRS-1, MAP kinase and Akt in the MCF-7,
MDA-MB-231 and HBL-100 cell lines. IGF-1 stimulated phosphory-
lation of IGF1R in BT-20 cells but did not alter the level of activation of
IRS-1, MAP kinase or Akt. The MEK1/2 inhibitor (PD 98059) and the
PI-3 kinase inhibitor (LY 294002) decreased the level of phosphory-
lation of MAP kinase and Akt in BT-20 cells. A phosphospecific anti-
body to tyrosine 896, the Grb2 SH2 binding site, shows that IRS-1 is
constitutively phosphorylated in BT-20 cells.
IGF-1 inhibited staurosporine-induced apoptosis in MCF-7, MDA-MB-
231 and HBL-100 cells but not in BT-20 cells. Inhibition of the IGF
signalling pathways with PD 98059 and LY 294002 sensitise MDA-
MB-231 cells to staurosporine-induced apoptosis. IGF-1 stimulated
growth in MCF-7 and MDA-MB-231 cells but not in BT-20 cells.
Conclusion Expression and activation of IGF signalling proteins vary
among the oestrogen nonresponsive cells. These differences will affect
the response of breast cancer cells to IGF targeted therapy. BT-20
cells provide a useful model for constitutive IRS-1 phosphorylation
which is reported to occur in breast tumours [3].
Acknowledgement  This project was funded by Breast Cancer
Campaign.
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Background  The Brk tyrosine kinase is expressed in approximately
two-thirds of human breast carcinomas, including lymph node
metastases, but neither in normal mammary tissue nor benign lesions.
This study tested the hypothesis that Brk is involved in regulating the
tumour cell environment during progression and investigated the
effects of suppressing Brk in breast carcinoma cells to determine in
which contexts Brk may be a valid therapeutic target.
Methods  We investigated whether Brk regulates the production of
extracellular matrix enzymes and angiogenic cytokines, and whether
Brk influences cell migration and chemotaxis. Studies to determine
whether modification of Brk expression affects tumour behaviour in vivo
are currently ongoing.
Results We have shown that suppression of Brk expression by RNA
interference significantly decreases the secreted level of the matrix
degrading enzyme MMP9 and the cytokine VEGFA, suggesting a role
for Brk in regulating some of the processes involved in metastasis
(proteolytic activity and neo-angiogenesis). As well as being able to
modify the extracellular environment and to regulate angiogenic
cytokine production, disseminating tumour cells must be able to survive
in the circulation. We have also shown that Brk suppression increases
the levels of cell death observed in breast carcinoma cells in
suspension culture, implicating Brk in promoting anchorage-
independent survival. In addition, suppression of Brk in suspension
culture alters the relative levels of Bcl-x proteins in favour of Bcl-xS. As
elevated Bcl-xL levels have been linked to chemotherapeutic resistance,
targeting Brk may have benefits in overcoming chemoresistance in
disseminating breast tumour cells.
Conclusions Taken together these data propose key functions for Brk
in breast tumour development and progression. Therapeutically
targeting Brk may have multiple effects in controlling the spread of
breast cancer.
Acknowledgement  This work was funded by a project grant from
Breast Cancer Campaign.
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Background  Bone metastasis is a frequent and often incurable
complication of breast cancer causing severe bone pain, pathological
fractures, spinal cord compression and hypercalcaemia. We have
focused on establishing the significance of the cell surface hyaluronan
receptor CD44 in underpinning the preferential metastasis of breast
cancer cells to bone. In prior in vitro studies, we demonstrated that
depletion of CD44 expression in breast cancer cells attenuates their
adhesion to bone marrow endothelial cells (BMECs). Our recent
experiments have also determined that the expression of CD44 is
elevated in the bone homing breast cancer subline MDA231BO
relative to that detected in the parental MDA231 breast cancer cell
line. Together these experiments suggest a physiological role for this
receptor in promoting the entry of breast cancer cells into the bone
microenvironment.
Methods  To further understand the potential significance of CD44
signalling to breast cancer metastasis, we established a tetracycline-
regulated CD44 expression system in the minimally invasive, CD44-
negative MCF7F cell line. Removal of tetracycline from the growth
media resulted in time-dependent increases in CD44 expression in
MCF7F cells, promoting increased cell invasion and migration
responses in addition to potentiating the adhesion of MCF7F cells to
BMECs. Subsequent microarray analysis was conducted using this
expression system to identify CD44/HA regulated genes in breast
cancer cells.
Results The expression and activation of CD44 was associated with
increased expression of a subset of genes implicated in metastasis
including proteolytic enzymes, growth factors and cytoskeletal proteins
(for example, cortactin). Interestingly, the cysteine protease cathepsin K
and the matrix metalloprotease MT1MMP were identified as CD44/HA
regulated genes. These proteases target collagen I, a major component
of the bone matrix whose degradation is a major consequence of
osteolytic metastasis of breast cancer. Consistent with their respective
metastatic potential, immunoblotting and ELISA based experiments
have confirmed that the expression of MT1MMP and cathepsin K are
both elevated in the MDA231BO bone homing cells relative to the
parental MDA231 cells. In addition, the expression of cathepsin K and
MT1MMP in the MDA231BO cells was significantly decreased upon
RNAi-mediated suppression of CD44. Quantitative real-time PCR,
immunoblotting and ELISA based experiments have also demonstrated
that the transcript and protein expression of cathepsin K and MT1MMP
increase in response to CD44/HA signalling in a panel of CD44-
expressing breast cancer cell lines (MDA231, MDA157 and MCF7F).
Currently, we are (i) investigating the mechanistic basis underpinning
the transcription of these target genes in breast cancer cells, (ii)
determining the functional significance of their overexpression in
facilitating breast cancer cells to degrade a collagen I matrix, and (iii)
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CD44 expression to osteolytic metastasis.
Conclusions It is consequently our hypothesis that CD44 may not only
promote extravasation into the bone marrow but may also confer an
osteoclast-like phenotype to the cancer cell, thus orchestrating the
ability of cancer cells to initiate and regulate the modification of the
bone matrix. The long-term objective of our research will be to
determine whether CD44 expression and that of its transcriptional
targets may be predictive for those breast cancer patients at higher risk
of developing skeletal disease and/or potentially lead to the
development of novel and more effective therapeutic strategies to
attenuate bone metastasis.
Acknowledgement This work is funded by Breast Cancer Campaign.
P19
Evaluation of migration-stimulating factor expression
for breast cancer diagnosis and prognosis
SJ Jones1, IR Ellis1, K Kankova1, AM Thompson2, P Preece2, 
S Kazmi2, SL Schor1, AM Schor1
1Unit of Cell and Molecular Biology, Dundee Dental School, University
of Dundee, Dundee, UK; 2University of Dundee Medical School,
Ninewells Hospital, Dundee, UK
Breast Cancer Research 2006, 8(Suppl 2):P19 (DOI 10.1186/bcr1574)
Migration-stimulating factor (MSF) is a novel angiogenic factor present
in most breast tumours but not in normal breast [1]. The purpose of this
study is to ascertain the presence of MSF in serum and to determine its
possible value for breast cancer diagnosis and prognosis. MSF
bioactivity has been detected in the serum of 90% (27/30) of breast
cancer patients, compared with 13% (4/30) of healthy controls. MSF-
specific antibodies have enabled the identification of MSF in serum
using immunoprecipitation and ELISA. Unexpectedly, quantification of
immunoreactive MSF in serum showed no difference between cancer
patients and controls. This discrepancy between bioactive MSF and
immunoreactive MSF is due to the presence of two forms of MSF in
serum, as well as a potent inhibitor of MSF (MSFI). Two isoforms of
MSF have been cloned; these differ by a 15-amino-acid deletion and
are referred to as MSF+aa and MSF–aa. MSF isolated from control
serum behaves like rhMSF+aa, in that it is inhibited by MSFI and
therefore is not bioactive in serum. MSF from cancer patient serum and
rhMSF–aa are not inhibited by MSFI, and are bioactive in serum. Our
next goal is to ascertain the biochemical difference between patient
and control MSF and to assess the diagnostic and prognostic value of
MSF-based serum measurements.
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Background Cellular interactions with the extracellular matrix (ECM)
control many aspects of cell function. The complex ECM protein
Tenascin-C (TN), which exists as multiple isoforms, is upregulated in
breast cancer. We previously have identified a change in the TN
isoform profile in breast cancer, with detection of two additional
isoforms – TN16 and TN14/16 – not seen in normal breast [1]. The
purpose of this study was to investigate directly the effects of these
tumour-associated TNC isoforms on breast cancer cell behaviour.
Methods A PCR-ligation approach was used to generate specific TNC
isoform sequences which were Flag tagged and inserted into a pCMV
vector. Transient transfection into breast cancer cell lines or primary
normal fibroblasts was confirmed by RT-PCR, western blotting and
immunohistochemistry. The effect of different TNC isoforms on breast
cancer cell invasion, proliferation and gene expression was analysed.
Results  Expression of TN16 and TN14/16 in breast cancer cells
(MCF-7, T47D, MDAMB231) resulted in significantly enhanced tumour
invasion compared with adult-type truncated TN, large TN and vector-
only controls. A similar increase in tumour cell proliferation was
detected. Coculture of tumour cells with primary breast fibroblasts
overexpressing TN16 or TN14/16 or conditioned medium from these
fibroblasts also led to enhanced tumour cell invasion. Expression of TN
resulted in upregulation of MMP-1; however, this was equivalent for all
TN isoforms. The invasion-promoting effect of TN16 and TN14/16 was
dependent on direct interaction between tumour cells and was blocked
by incorporation of anti-TN blocking antibodies. Furthermore, TN
appears to be essential for tumour cell invasion, since with all isoforms
invasion was minimal in the presence of anti-TN antibodies.
Conclusion This study has demonstrated that the tumour-associated
TN isoforms TN16 and TN14/16 significantly enhance breast cancer
cell invasion and that blocking TN inhibits invasion. We aim to further
investigate the invasion-promoting activity of these isoforms and to
explore their therapeutic potential in more sophisticated tumour
models.
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Four transmembrane domain proteins of the tetraspanin superfamily are
the organisers of specific microdomains at the membrane (tetraspanin-
enriched microdomains (TERM)) that incorporate various trans-
membrane receptors and modulate their activities. Tetraspanin CD82
is frequently downregulated or absent in the metastatic cancers. In
human prostatic cancer, downregulation of CD82 has been correlated
with tumour progression, providing evidence for its role as a metastasis
suppressor. We have shown recently that the overexpression of
metastasis suppressor tetraspanin CD82/KAI1 led to the attenuation of
epidermal growth factor receptor (EGFR) signalling, to an increased
internalisation rate of the receptor and to the redistribution of EGFR at
the plasma membrane [1]. Moreover, our latest data suggested that the
effect of CD82 on the EGFR signalling is mediated by gangliosides [2].
Gangliosides (a subclass of glycosphingolipids) are essential structural
components of distinct microdomains at the membrane. In addition,
these glycosphingolipids are also involved in the regulation of signalling
and tumour progression.
We currently demonstrate that inhibition of the glycosphingolipid
biosynthetic pathway with specific inhibitors of glucosylceramide
synthase (NB-DGJ and PPMP) resulted in specific weakening of the
interactions involving tetraspanin CD82, including CD82–EGFR
association. Furthermore, ectopic expression of the plasma membrane-
bound sialidase Neu3 in mammary epithelial cells destabilised CD82-
containing complexes. The destabilisation of these complexes correlated
with the redistribution of the proteins within the plasma membrane.
Importantly, depletion of gangliosides affected EGF-induced signalling
only in the presence of CD82. Taken together our results provide strong
evidence that gangliosides play an important role in supporting the
integrity of CD82-enriched microdomains [3]. Furthermore, these data
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mammary epithelial cells is controlled by distinct mechanisms.
In further experiments we are going to investigate the role of TERM,
and specifically CD82-enriched microdomains, in the signalling through
the ErbB3 receptor. The ErbB3 receptor is considered a major partner
for the ErbB2 receptor and is involved in the progression of breast
cancer.
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Oestrogen is a major requirement for the growth of human breast
cancer cells. Current treatments are aimed at reducing the action of
oestrogen with antioestrogen therapy. However, many patients are able
to progress to a state where they no longer respond to antioestrogen
therapy. Long-term growth of breast cancer cell lines in the absence of
oestrogen leads to the development of acquired resistance where the
cells are able to grow without the addition of oestrogen, they can still
be inhibited by antioestrogens and there is no loss of oestrogen
receptor alpha. The aim of this work was to identify novel molecular
markers that could indicate impending failure to endocrine therapy.
Adrenomedullin is a 52-amino-acid peptide which may play a role in
tumour survival and angiogenesis. Microarray data comparing
oestrogen-maintained MCF7 cells with long-term oestrogen-deprived
MCF7 cells showed that the expression of adrenomedullin mRNA was
12-fold upregulated after more than 1 year of culture in the absence of
oestrogen. Real-time RT-PCR data were able to confirm the increase in
the levels of adrenomedullin mRNA in long-term oestrogen-deprived
cells. Immunocytochemistry using a monoclonal antibody specific for
adrenomedullin was also able to show an increase in the amount of
adrenomedullin protein in long-term oestrogen-deprived cells.
Furthermore, long-term treatment of oestrogen-maintained cells with
tamoxifen and fulvestrant led to an increase in the level of
adrenomedullin mRNA which was not observed in long-term oestrogen
deprived cells. Further validation with tumour samples is required to
examine the importance of adrenomedullin as a possible marker of
endocrine resistance in human breast cancer.
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Breast cancer is the most common cancer in women and is increasing
in both the developed and developing countries. There is an urgent
need to understand the precise mechanisms of tumour development in
breast cancer, to develop new treatment strategies and to identify
predictive markers for tumour aggressiveness and therapy resistance.
A protein called protein kinase B (PKB, also called Akt) is frequently
elevated in breast cancers and has been implicated as a key player in
breast cancer development and progression. The activation level of
PKB is also thought to correlate with patient outcome. However, the
function of the three isoforms of PKB in mediating the crucial
responses is unknown. We have developed a set of antisense
phosphorothioate oligonucleotide probes that target antisense-active
regions in PKB and that enable >90% knockdown of all three known
PKB isoforms (alpha, beta and gamma), either individually or in various
combinations, including removal of all three isoforms together. We
have demonstrated that these agents specifically and potently prevent
the growth of breast cancer cells. Application of these antisense
agents offers a unique opportunity to understand how PKB works and
contributes to breast cancer, and to provide insight into the role of
signalling by individual PKB isoforms in breast cancer cells. Such work
may also identify clinically relevant markers of disease, thereby enabling
better predictors of patient outcome, and provide the necessary
intellectual framework for the development of PKB-isoform selective
inhibitors (for example, antisense oligonucleotides, small chemical
inhibitors) as novel therapeutic agents.
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Oestrogen receptor (ER) alpha remains the only reliable biological
prognostic marker in breast cancer. A sister molecule, ERβ, has been
described, but while ERα predicts a favourable disease outcome, the
utility of ERβ as a clinical prognosticator is unclear. ERβ exists as five
isoforms (ERβ1–ERβ5), each with a unique exon 8. The aim of our
research is to understand the function of ERβ and its isoforms in the
normal mammary gland and in breast cancer. We have previously
shown high expression of total ERβ in normal gland with declining
expression in the transition to breast tumours. LOH analysis in 27
paired samples of tumours and normal breast showed no correlation
between LOH and loss of total ERβ expression by immuno-
histochemistry, indicating the latter was not a mutational event. Instead
this was due to methylation as treatment of ERβ-negative cell lines
resulted in re-expression of total ERβ at the protein and mRNA level.
Furthermore, using methylation-specific PCR, ERβ was methylated in
up to 50% of all tumours but not in matched normal gland. Recent
immunohistochemical analysis of isoforms ERβ1–ERβ5 using specific
well-validated antibodies in 777 invasive breast cancers with long-term
clinical follow-up showed nuclear expression of ERβ2 was significantly
correlated with tumour size, grade, NPI, overall survival, distant
metastasis, death from breast cancer and ERα, PR, AR and BRCA1
expression. ERβ5 was predominantly expressed in high-grade cancers
and showed a significant positive correlation with ERβ1. ERβ1,
however, was not associated with any other pathological parameters.
Using an antibody to detect total ERβ, positive tumours were more
likely to develop distant metastasis. Notably, this study also highlighted
the importance of cytoplasmic expression of ERβ in dictating outcome,
a feature that had previously been reported but the significance of
which had not been elucidated. In our study cytoplasmic staining,
whether alone or in combination with nuclear staining, was associated
with decreased overall survival. In summary, ERβ and its variants do
seem to influence the breast cancer outcome. The data accumulated
thus far and the importance of its sib ERα in directing breast cancer
therapy create an imperative for us to continue to unlock its secrets.
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Background  The objective was to study the relationship between
CXCR4 expression (total and conformational subsets) and disease
outcome in malignant breast disease. Initially, a retrospective study
evaluating the clinical significance of CXCR4 expression (as determined
by immunohistochemistry and immunofluroscence) with histopathological
grade and clinical outcome of breast cancer patients were evaluated.
Methods Tumour specimens from breast cancer patients treated at the
Breast Unit at Guy’s Hospital London, with prospectively acquired
long-term follow-up (25 years) were used in this study.
Using tissue microarrays (TMAs), of primary breast tumour specimens
from a series of 252 invasive ductal and lobular carcinomas were
immunolabelled for CXCR4.  Polyclonal antibodies to human CXCR4
(Anti-Human CXCR4 ARP4016){CXCR4 peptide ARP 7039 N-
terminal extracellular domain (1-38)} and two further anti-human
CXCR4 cytoplasmic antibodies against two distinct peptides based on
the membrane proximal sequence (GAKFKTSAQHALTSVSRG) and
distal cytoplasmic sequence (VSTESESSSFHSS) of huCXCR4
cytoplasmic domain, were used to detect CXCR4.
The immunohistochemical detection of CXCR4 expression, was
assessed by 2 independent pathologists (with consensus agreement).
Both the proportion and intensity of expression was recorded for the
total and subpopulations of CXCR4 recognised by ARP4016 and the
two cytoplasmic antibodies, respectively.
For immunofluroscence the average fluorescence intensity/unit area of
cells stained with the respective antibodies were plotted and quantified.
Results The proportion and intensity of invasive cells expressing CXCR4
was significantly less in Grade III infiltrating ductal carcinoma compared
with Grades I, II and lobular types (P < 0.0001 by Kruskal-Wallis). There
is a complex relationship between survival and total CXCR4 expression,
with a subset of high CXCR4 expressing, Grade III tumours showing a
trend towards poor prognosis.  This association will be further elucidated
by results of the CXCR4 cytoplasmic antibody staining.
Conclusions CXCR4 was expressed uniformly across a spectrum of
normal, and a panel of invasive breast tumour cells but only a subset of
Grade III tumours expressing high CXCR4 correlated with poor
prognosis. It may be that only highly invasive cells that are metastatic
and very poorly differentiated express functional CXCR4 receptors.
CXCR4 function is subject to complex and potentially tightly controlled
regulation in breast cancer cells via differential G protein receptor
complex formation and this regulation may play a role in the transition
from non metastatic to malignant transformation [1]. The application of
new antibody tools and optical technologies to these pathological
samples will assist the discovery of new biomarkers that will report on
the function of CXCR4 in situ.
Acknowledgement  This study was funded by Breast Cancer
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Mammary cancer can develop for many reasons; one is the exposure to
environmental carcinogens and/or steroid hormones. The cytochrome
P450 enzyme family catalyses not only the metabolism of a wide range
of carcinogens but is also involved in the metabolism of steroids. This
process alters their steroidogenic properties, a mechanism important
for mammary carcinogenesis.
At the centre of this research are cytochrome P450 1B1 (CYP1B1)
and cytochrome P450 1A1 (CYP1A1). Unlike many other P450s,
these isoforms are expressed extrahepatically. CYP1B1 protein is
found to be overexpressed in tumours compared with the corres-
ponding healthy tissues. Special regulatory mechanisms are likely to
cause this difference.
In this study we employed TaqMan analysis, immunoblotting and
reporter assays to investigate the expression patterns of CYP1B1 and
CYP1A1 in a panel of breast cancer cell lines derived from different
stages of mammary carcinomas. Furthermore, we investigated the
expression of these P450s in cell lines derived from primary human
mammary epithelial cells (HMECs) that have been transfected with
various combinations of oncogenes and telomerase. In the transformed
HMECs we found that the expression of CYP1B1, CYP1A1 and their
inducibility by TCDD was differentially affected by the different
oncogenes. We are presently investigating the regulatory mechanisms
that cause this response.
In a second investigation, we analysed the relevance of P450
expression for mammary-tumour development and tumour therapy. For
this purpose we have developed MCF-7-derived cell lines in which the
expression of CYP1A1 and CYP1B1 can be switched on by treatment
with low doses of doxycycline. We demonstrated that expression of
these P450s altered the effects of estrogens and antiestrogens on cell
cycle and apoptotic markers. Currently, the MCF-7-derived cell lines
are being grown in xenografts. P450 expression will be induced by
doxicycline in the drinking water, and animals will be treated with or
without tamoxifen. Subsequently, the effects of P450 expression on
tumour growth, angiogenesis and apoptosis will be measured.
It is anticipated that the results of these investigations will greatly
enhance our understanding about the aetiology of breast cancer and
may provide strategies to improve treatment.
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Background  The Prospective Study of Treatment Outcomes in
Sporadic versus Hereditary Breast Cancer (POSH) will have recruited
2,000 women over a 5-year interval from over 100 participating UK
centres who have newly diagnosed breast cancer before age 41 years.
Methods  The first 1,200 cases from the study in whom diagnostic
pathology reports were submitted were analysed. We looked at the
distribution of the reported tumour phenotype (major prognostic
histopathological features) in women aged ≤35 years (43% of the total
cohort) compared with women diagnosed age 35–40 years in order to
further explore biological explanations for the known worse clinical
prognosis for women aged under 36 years compared with older
women. The χ2 statistic was used to compare groups; genetic risk for
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genetic model rather than a gene specific model. The highest genetic
risk groups are likely to harbour most of the BRCA1 and BRCA2 gene
carriers.
Results  The majority of women at all ages were treated with
anthracycline-based adjuvant chemotherapy and there was no
difference in the choice of immediate surgical management between
either age groups or between genetic risk groups.
Significantly more women in the ≤35 years age group had grade 3
(P < 0.01) and ER-negative (P < 0.02) tumours compared with women
diagnosed in the older age group (>35 but ≤40 years). There was no
significant difference in tumour size or lymph node status based on age
categories. Compared with women with no family history, women
falling into the 10% of the cohort estimated from family history to be
most likely to carry BRCA1 or BRCA2 gene mutations, high genetic
risk women had significantly more grade 3 tumours (P < 0.001) and a
nonsignificant trend towards more ER-negative tumours.
Conclusion  These data are from a preliminary pending systematic
pathology review but bear out the observations by others that very
young age of onset and host genotype affect the tumour phenotype
and are therefore likely to have an impact on prognosis. Longer follow-
up of this cohort is planned and outcome data based on age and
based on genetic risk category and genetic mutation status will be
available in a further 12 months time.
Acknowledgements Funding for the work presented in this abstract
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We are performing comprehensive association studies of single
nucleotide polymorphisms (SNPs) in genes in the transforming growth
factor beta (TGFβ) signalling pathways in a female breast cancer
case–control study.
TGFβ acts as a suppressor of primary tumour initiation but is implicated
as a promoter of the later malignant stages. A hypothesis explaining
this dual action proposes that TGFβ acts through the ubiquitous
ALK5/SMADs2&3 signalling pathway to inhibit proliferation of primary
tumour cells, but acts through the endothelial-specific ALK1/
SMADs1&5 pathway to promote angiogenesis, which is required for
progression to malignancy.
In a previous study we showed that a SNP generating a leucine to
proline substitution in the signal peptide of the TGFB1 protein was
associated with a 1.24-fold increase in the risk of invasive breast
cancer, with increased levels of the protein in human serum and with a
2.8-fold increase in amount of the protein secreted in vitro.
It is also plausible that other genes in the TGFβ signalling pathways
might be associated with altered risk of breast cancer. We have
initiated systematic breast cancer association studies with SNPs in the
genes encoding proteins directly implicated in TGFβ signalling
pathways, including the LTBP and TGFβ isoforms, ALK1, ALK5 and
TGFBR2 receptors, and SMADs 1–7. A comprehensive SNP tagging
approach was used to select variants for genotyping in a staged study
design using up to 4,600 cases and 4,600 controls, all from the East
Anglian region of the United Kingdom (>98% of northwestern
European ancestry).
To date, nine genes (TGFB1, TGFB2, TGFB3, ALK1, ALK5, TGFBR2,
Endoglin, SMAD2 and SMAD4) have been analysed. From 285 common
SNPs (minor allele frequency >0.05), identified from the International
HapMap project data, 83 tagging SNPs have been defined and
genotyped. Statistically significant associations with cancer
susceptibility have been identified with at least one variant in five of the
genes. The TGFB2, TGFB3, Endoglin  and SMAD4  genes are not
associated. A further eight genes will be studied.
Acknowledgements Breast Cancer Campaign funded this work. The
authors are grateful to the SEARCH Breast Cancer Study Team for
sample collection.
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Background Postmenopausal breast cancer risk increases twofold in
women who gain significant amounts of weight [1] and there is
evidence that energy restriction may reduce risk [2]. Animal studies
indicate that intermittent energy restriction (IER) reduces risk and may
be superior to continuous energy restriction (CER) [3]. We have shown
chronic energy restriction reduces biomarkers of breast cancer in
women at risk but is hard to maintain. We hypothesise that IER may be
superior to CER in reducing biomarkers of breast cancer risk and may
also be more acceptable to women.
Methods We are undertaking a 6-month randomised trial to compare
the two approaches in 104 premenopausal women aged 30–45 years
at high risk of breast cancer because of adult weight gain >7 kg.
Women will be randomly assigned to either CER (75% estimated
energy requirements: ~1,500 kcal 7 days/week) or IER (75%
estimated energy requirements: 650 kcal for 2 days and ~1,800 kcal
5 days/week) over 6 months. Study end points will be measures of
insulin sensitivity (HOMA, SHBG and testosterone), potential breast
cancer growth factors (IGF axis, leptin and adiponectin), inflammatory
markers (C-reactive protein and sialic acid), oxidative stress marker
(urinary F2 isoprostane), weight and body composition (waist/hip
circumference, fat free and total fat mass). The relative acceptability of
IER and CER will be assessed using a quality of life questionnaire
(RAND SF-36) and scales of behaviour change and adherence. The
relative efficacy and acceptance of intermittent and chronic calorie
restriction will inform future weight loss programmes to prevent breast
cancer. Thirty-seven women have currently been recruited to the study
(18 CER and 19 IER) and recruitment is planned to be completed by
December 2006.
Acknowledgements  This study is funded by the Breast Cancer
Campaign, the World Cancer Research Fund and Genesis.
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Background Jacobs and Bovasso reported [1] that maternal death in
childhood and chronic, severe depression in adulthood was associated
with subsequent breast cancer. We examined the effects of parental
loss in childhood and psychiatric disorder in adult life on breast cancer
risk using a national birth cohort study.
Methods  Eighty-three cases of breast cancer were diagnosed in a
study of 2,253 women followed from birth to age 59 years. Cox’s
proportional hazards models were used to test whether breast cancer
rates were higher in women who experienced parental death and
divorce before age 16, psychiatric illness between 15 and 32 years,
symptoms of anxiety and depression at 36 years, or use of anti-
depressant medication at 31 or 36 years than in women who did not
have these experiences.
Results  There was no overall association between parental death,
parental divorce, or psychiatric disorder on the incidence of breast
cancer. There was some evidence that women with severe psychiatric
illness were more likely to develop breast cancer early. The interaction
between parental divorce and severe psychiatric illness was non-
significant (P = 0.1); however, the group who experienced both these
events had an increased breast cancer risk compared with those who
experienced neither (HR = 2.64, 95% CI = 1.13–6.19) [2].
Conclusions  Our study does not provide strong support of the
hypothesis that early loss or adult psychiatric disorders are associated
with breast cancer. A meta-analysis is needed that uses data from all
available cohort studies and investigates possible interactive effects on
breast cancer risk.
Acknowledgements RH, SB, MEJW, and DK are funded by the UK
Medical Research Council. GM is funded by Breast Cancer Campaign
and the World Cancer Research Fund, UK.
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Background We aimed to assess the clinical significance of tumour-
infiltrating FOXP3+ regulatory T cells (TR) in breast cancer patients
with long-term follow-up.
Methods FOXP3+ TR were detected by immunohistochemistry with
our new FOXP3 monoclonal antibody, 236A/E7. Numbers of FOXP3+
lymphocytes in tissue microarray cores from pure ductal carcinoma in
situ (DCIS) (n = 62), from invasive breast cancer (n = 237) or from
comparable areas of normal terminal duct lobular breast tissue from
patients without cancer (n = 10) were determined. A median cutoff
value of 15 defined patients with high numbers of TR.
Results  TR numbers were significantly higher in DCIS and invasive
breast carcinomas when compared with normal breast, with invasive
tumours having significantly higher numbers than DCIS (P = 0.001).
High numbers of FOXP3+ TR  identified patients with DCIS at
increased risk of relapse (P = 0.04) and patients with invasive tumours
having both shorter relapse-free (P = 0.004) and overall survival
(P = 0.007). High TR numbers were present in high-grade tumours
(P < 0.001), in patients with lymph node involvement (P = 0.01) and in
estrogen receptor alpha (ER)-negative tumours (P = 0.001). Impor-
tantly, quantification of FOXP3+ TR identified a group at high risk of
relapse, within the so-called good prognostic group of ER-positive
patients (P = 0.005) and these patients have a prognosis as poor as
those that lack ER expression. Multivariate analyses, in ER-positive
patients, demonstrated that greater TR  numbers independently
conferred a significantly higher hazard ratio than that of tumour grade
and nodal status for relapse-free and overall survival, respectively.
Unlike conventional clinicopathological factors, high numbers of
FOXP3+ TR identified patients at risk of late relapse after 5 years
disease-free survival.
Conclusion These findings indicate that quantification of FOXP3+ TR
in breast tumours is valuable for assessing disease prognosis and
progression, and represents a novel marker for identifying late-relapse
patients who may benefit from aromatase therapy after 5 years of
tamoxifen treatment. Furthermore, tumour vaccination approaches in
combination with targeting TR cells are just entering clinical trials and
our data strongly suggest that such therapy would be beneficial for a
significant proportion of breast cancer patients.
Acknowledgement  The authors would like to thank Breast Cancer
Campaign for their research support.
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Background  Aptamers are novel oligonucleotide-based recognition
molecules which can bind to almost any target, including extracellular
proteins, antibodies, peptides and small molecules. Aptamers can be
rapidly generated, and offer reduced immunogenicity, good tumour
penetration, rapid uptake and clearance, and can thus be used as
alternatives to monoclonal antibodies in molecular targeted radio-
therapy and diagnostic imaging.
Methods We have previously reported the isolation of high affinity and
specificity DNA aptamers against the protein core of the MUC1
glycoprotein as a tumour marker on breast cancer cells. Once
conjugated with a chelating agent and labelled with a radionuclide
(99mTc or 188Re), such aptamers can be particularly useful in the
diagnosis and targeted radiotherapy of breast cancer. The conjugation
is achieved using standard peptide coupling reactions between an
amino modification on the aptamer and the carboxylic group on the
ligands.
Results We have coupled the aptamer with the highest affinity for the
MUC1 glycoprotein to different ligands (MAG2 or meso-2,3-di-
mercaptosuccinic acid) and labelled it with 99mTc and 188Re to obtain
stable complexes. An efficient and convenient labelling of the aptamer
with short half-life radioisotopes was achieved as the last step of the
synthesis (postconjugation labelling).
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binding properties and the resulting complexes are highly stable in vivo
both in terms of nuclease degradation and leaching of the metal. The
presence of more than one molecule of aptamer per complex or the
conjugation of the aptamer to high molecular weight polyethylene
glycol modifies the pharmacokinetic properties of the radiolabelled
products, allowing the complex to remain longer in circulation and thus
offering improved tumour imaging properties and further possibilities
for development into a targeted radiopharmaceutical for breast cancer
therapy.
Acknowledgement The authors thank Breast Cancer Campaign for
financial support.
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Background Post-translational modification of histones is a common
mode of regulating chromatin structure and gene activity in normal
tissues. In malignant cells, aberrant modifications through acetylation
and methylation at the promoter regions of individual histones have
been reported. Global changes in histone modification have recently
been shown to be predictive of clinical outcome in prostate cancer.
However, the expression and prognostic significance of modified
histones in breast cancer has not been previously explored.
Methods  Global histone modification in a large well-characterised
series of breast carcinomas (n = 880) with long-term follow-up was
therefore assessed using immunohistochemistry and tissue microarray.
Specific antibodies were used to detect acetylation of H3 (Lys9 and
Lys18) and H4 (Lys12), and dimethylation of histone H4 (Arg3) and H3
(Lys4). The presence of these chromatin ‘marks’ was correlated with
clinicopathological variables and patients’ outcome.
Results  Reduced levels of histone acetylation/dimethylation were
observed in medullary-like carcinomas, whereas they were readily
detected in lobular and tubular carcinomas. Reduced global histone
acetylation/dimethylation was significantly associated with established
poor prognostic variables; larger tumour size, higher stage, recurrence,
distant metastases and higher mortality rate. Survival analyses showed
low detection of the histone modifications, with the exception of
acetylated H3K9, was associated with shorter overall survival and
shorter disease-free interval.
Conclusion Our results show, for the first time, that global changes in
specific histone modification patterns may play an important role in
breast cancer development and progression and their reduced
expression is associated with poor prognosis and shorter survival.
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Background  Radiotherapy (RT) following conservation surgery for
breast cancer has been proven to improve both local control and
survival. Currently, the challenge is to minimise RT-induced side effects
without losing efficacy. Conventional 2D RT breast plans can lead to
substantial dose inhomogeneities, which may cause a worse cosmetic
result. This is important to patients, as a poor cosmetic result can
cause significant psychological morbidity. Planning studies have shown
that breast dose homogeneity can be improved with 3D planning and
intensity modulated radiotherapy (IMRT). However, there is very little
evidence regarding the clinical benefit of IMRT for breast cancer. This
unique NCRN-adopted randomised controlled trial will test the clinical
benefit of IMRT for women with early breast cancer.
Methods  The primary question is: does correction of dose
homogeneity using forward-planned IMRT improve the cosmetic
outcome in patients with early breast cancer? Patients with significant
dose inhomogeneities with 2DRT are randomised to IMRT or standard
2D RT. High-quality normal tissue toxicity and cosmesis data are being
collected, including a novel analytical method of breast volume
measurement using a 3D laser camera.
Results Eight hundred and eighty-five patients have been recruited to
date, and accrual of 1,000 patients is on target for January 2007. A
high-quality radiographer-led 3D breast radiotherapy service has
developed as a direct result of the trial. Blood DNA samples from trial
patients will enable investigation of individual genetic variation in
normal tissue radiosensitivity within a multicentre translational radio-
genomics study.
Conclusion The results from this trial could provide impetus to improve
the quality of breast radiotherapy for many women worldwide. The DNA
database will greatly contribute to the ultimate aim of individualised
radiotherapy based on genetics.
Acknowledgement Jenny Wilkinson, Trial Radiographer, is funded by
Breast Cancer Campaign.
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Objective The purpose of this study is to explore possible molecular
and cellular mechanisms involved in the development of resistance to
Herceptin in breast cancer patients.
Background Herceptin is a humanized monoclonal antibody targeted
against the human epidermal growth factor receptor c-erbB-2 (HER-2)
which is overexpressed in approximately 25–30% of invasive breast
cancer. Herceptin recognizes an epitope on the extracellular domain of
c-erbB-2 and blocks downstream signaling. Approximately 50% of
patients respond to Herceptin therapy; however, the majority of these
will demonstrate disease progression within 1 year of treatment
initiation. Several molecular mechanisms contributing to Herceptin
resistance have been proposed. This research aims to define the
effects of Herceptin on subcellular c-erbB-2 receptor trafficking.
We have created a c-erbB-2  plasmid fused to Yellow Fluorescent
Protein (c-erbB-2-YFP) and an epidermal growth factor receptor fused
to Green Fluorescent Protein (EGFR-GFP). Both constructs were
sequenced and the correct sequence obtained. Both constructs were
shown to react with specific antibodies and to have the predicted
molecular weight using western blotting.
Methods Both EGFR-GFP and c-erbB-2-YFP plasmids were used to
transiently transfect COS-7 cells. Time-course studies using low-light
fluorescent microscopy revealed maximal membrane receptor
expression between 18 and 24 hours after transfection. Herceptin
immunoglobulin (Genentech Inc, South San Francisco, USA) was
conjugated to Alexa Fluor 568 (Invitrogen Molecular Probes, Inc, USA)
to allow visualization of the antibody. After 20 hours, c-erbB2-YFP
transfected COS-7 cells were incubated with Alexa Fluor-labeled
Herceptin for 2 hours. Serial fluorescent images were recorded over
12 hours allowing real-time visual localization of both the receptor and
Herceptin.
Results  These preliminary studies indicate that Herceptin induces
receptor internalization. Further studies are planned whereby cells will
be co-transfected with both c-erbB2-YFP and EGFR-GFP and
exposed to an anti-EGFR antibody as well as Herceptin. Confocal
microscopy will be utilized in mapping the fate of receptors and their
antibodies. It may be that this dual targeting will exaggerate receptor
internalization and degradation.
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mammalian cells and receptor trafficking can be observed using digital
fluorescent microscopy. In addition, we have fluorescently labeled
Herceptin and its ability to bind c-erbB-2 is retained. This study of
receptor and antibody trafficking may lead to further knowledge of
Herceptin’s mechanism of action as well as that for drug resistance
and the possible effects of the use of combined therapies.
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Background Breast cancer patients commonly receive a combination
of different therapies; however, our understanding of how such
combined treatments work is incomplete. In an attempt to optimize
treatment strategies we have focused on determining how anticancer
agents can be combined in order to induce maximum levels of tumour
cell death. The antiresorptive agent zoledronic acid (zol) (Novartis
Pharma, Basel, Switzerland) and the chemotherapeutic agent
doxorubicin (dox) (Parmachemie BV, Haarlem, The Netherlands) have
been shown to synergistically increase apoptosis in breast cancer cells
in vitro. In order to determine whether sequential treatment with dox
and zol could have potential clinical relevance and to determine the
cellular mechanisms responsible for this synergy, we have further
investigated combination treatments in vitro and in vivo.
Methods To enable visualization of intratibial tumours, MDA MB 436
breast cancer cells were stably transfected with GFP (MDA GFP 2
cells). Following sequential treatment with dox and zol, levels of MDA
GFP 2 apoptosis were assessed by microscopic analysis following
Hoechst and propidium iodide (PI) staining and by flow cytometry after
annexin and PI staining. For in vivo dose–response studies, MDA GFP
2 cells were inoculated subcutaneously into the right flanks of female
MF1 nude mice (n = 8). Mice were administered 2.5, 3, 30 or 150 µM
zol intraperitoneally, or 2, 4 or 8 mg/kg dox intravenously. Combination
studies were carried out against subcutaneous (n = 16) and intratibial
(n = 8) MDA GFP 2 xenografts using a dosing regime of 2 mg/kg dox
and/or 2.5 M zol once per week for 6 weeks, with zol being
administered 24 hours after dox. The tumour volume was measured
once per week for 6 weeks and mice were sacrificed 24 hours
following final treatment.
Results and conclusions In vitro sequential treatment with dox then
zol synergistically increased apoptosis in MDA GFP 2 cells. In vivo
combination treatment with dox then zol resulted in a significant
reduction of tumour growth compared with control mice or mice
treated with dox or zol alone.
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Background  Transforming growth factor beta (TGFβ) is a multi-
functional cytokine that regulates a wide variety of cellular processes,
such as proliferation, differentiation and apoptosis. The role of TGFβ in
breast cancer is complex. In the early stages of the disease TGFβ
functions as a tumour suppressor, but later the protein switches to a
prometastatic factor, suggesting that the inhibition of TGFβ activity may
be of benefit in the treatment of stage IV metastatic disease. There is
much interest at the present time in the development of strategies to
inhibit the TGFβ signalling pathway for the treatment of metastatic
cancer and other diseases.
We are using an in silico approach to identify small molecules capable
of disrupting the TGFβ signalling pathway. In particular, we are
searching for compounds with the ability to bind to the same site on
the type II receptor (TβR-II) as TGFβ itself, thus preventing recruitment
of the type I receptor, effectively blocking the ensuing signalling
cascade.
Methods  Molecular docking was performed using the commercially
available docking program FlexX [1]. We attempted to dock 250,251
molecules from the NCI compound library against the extracellular
domain of TβR-II, coordinates for which were taken from a crystal
structure of the TGFβ3:TβR-II complex (Protein Data Bank accession
number 1KTZ [2]). The consensus scoring function embedded within
the software was used to assign each compound with a score,
allowing them to be ranked, such that the highest ranking compounds
could be prioritised for in vitro assessment.
The ability of the compounds to inhibit TGFβ signalling was tested in a
cell-based reporter assay [3]. Any compounds shown to bring about a
reduction in TGFβ signalling were taken forward for IC50 determination,
performed in tandem with an MTT cell viability assay.
Results  From the NCI compound database, a total of 219,567
molecules were successfully docked and scored by FlexX. Eighteen of
the highest-ranking 40 compounds were obtained from the NCI
Developmental Therapeutics Program and assessed for their ability to
inhibit TGFβ signalling. One of these compounds was shown to inhibit
TGFβ signalling without displaying any significant cytotoxicity.
Conclusion We have discovered a novel, small molecule capable of
inhibiting TGFβ signal transduction. Our current work is focused on
identifying the mode of action of this molecule and on the exploration of
the surrounding chemical space, with a view to discovering more
potent compounds and developing structure–activity relationships.
Acknowledgements The authors would like to thank Breast Cancer
Campaign for funding and the NCI Developmental Therapeutics
Program for supplying the small molecules.
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Background  The MUC1 mucin represents an excellent target for
breast cancer immunotherapy since it is overexpressed and under-
glycosylated in 90% of cases. To exploit this, we are developing a
genetic approach to retarget T-cell specificity to MUC1, using chimeric
antigen receptor (CAR) technology.
Methods A panel of MUC1-specific CAR have been generated using
scFv derived from the SM3 and HMFG2 hybridomas. All CAR were
generated by overlap extension PCR and incorporate a fused signalling
domain comprising CD28 and CD3ζ. Stable CAR expression was
Available online http://breast-cancer-research.com/supplements/8/S2
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expression vector, following activation using PHA or CD3+28 beads.
Results  Our first-generation MUC1-specific CAR, termed S28z,
contained an SM3 scFv fused to a CD28 hinge. Surprisingly, however,
S28z grafted T cells were poorly activated by a MUC1 + IgG fusion
protein or MUC1 expressing T47D breast cancer cells. By contrast,
S28z enabled T-cell activation when the MUC1 epitope was presented
as a crosslinked peptide. Together, these findings suggested that
steric hindrance and/or poor access to the epitope are limiting factors
in CAR-based targeting of MUC1. To overcome this, a flexible mono-
meric hinge derived from IgD was introduced, thereby creating SD28z.
Despite reduced stability, the SD28z CAR enabled T cells to proliferate
in response to MUC1 glycoforms found in breast cancer. Stability of
SD28z was further improved by inclusion of IgG1 Fc sequences in the
extracellular domain (giving SDF28z). SDF28z exhibited greater
functional activity, enabling T cells to kill T47D tumour cells. In a
second approach to optimize function, a scFv was cloned from the
MUC1-specific HMFG2 hybridoma. HMFG2 binds breast tumour cells
with greater intensity than SM3. In keeping with this, all HMFG2-
derived CAR exhibited greater functional activity than their SM3
counterparts. In the MUC1-specific CAR that exhibits greatest activity
(HDF28z), an HMFG2 scFv has been fused to the IgD hinge and IgG1
Fc (HDF28z). HDF28z grafted human T cells exhibit potent cytolytic
activity against MUC1 expressing breast cancer cells, associated with
cytokine production and subsequent T-cell clonal expansion.
Conclusion  Following extensive protein engineering, we have
developed a stable and highly potent CAR to retarget human T cells to
the ubiquitous tumour antigen MUC1.
Acknowledgements This work is supported by a Health Foundation/
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Background  Zoledronic acid (ZOL) (Novartis Pharma, Basel,
Switzerland) is a N-containing bisphosphonate currently used in the
treatment of osteoporosis and tumour-induced bone disease in a wide
range of solid and haematologic malignancies. Previous studies have
shown that ZOL interferes with endothelial cell (EC) function; however,
little is known about the effect of ZOL on ECs of the microvascular
network that resemble the tumour vasculature. Taxol (Bristol-Myers
Squibb Company, New York, USA), also known as paclitaxel (PAC)
(Sigma, UK), is a chemotherapeutic agent currently used in anticancer
therapy. Previous studies on tumour cells have shown that it
specifically interferes with microtubule assembly. Its antiangiogenic
properties  in vitro or  in vivo remain unestablished. Combination
treatments with ZOL and PAC have also been shown to have a
synergistic effect on apoptosis in tumour cell lines.
Methods We have investigated the effects of ZOL and PAC on ECs in
vitro, both alone and in combination, therefore determining the effects
on EC death and the ability of ECs to adhere onto membranes of
various components of the extracellular matrix as well as on EC
proliferation, migration and Rap1a prenylation.
Results Human dermal microvascular ECs (HuDMECs) were treated
with increasing doses of ZOL (0–50 µM) and PAC (0–10 nM) alone
and in combination. ZOL affected EC proliferation (50 µM for 48 and
72 hours, P < 0.05), tube formation (50 µM for 24 hours, P < 0.05) and
Rap1a prenylation. EC adhesion or apoptosis was not affected. PAC
interfered with EC tube formation but not proliferation (24 and
48 hours). PAC also affected apoptosis; however, the exact level was
dependent on the cell batch. Apoptosis was induced (50 µM ZOL and
2 nM PAC for 24 hours, P < 0.05) in cultures treated with ZOL and
PAC together. Migration was inhibited at very low doses of PAC
(500 pM) and 25 µM ZOL with combination treatment.
Conclusions These data suggest that combinations of ZOL and PAC
may have increased antiangiogenic effects compared with that caused
by the single agents.
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Background The aim was to explore the experiences of women with
breast cancer in relation to routine follow-up appointments in different
settings, including the issues surrounding discharge from hospital care.
Methods A qualitative focus group and interview study in the area of
Norfolk serviced by the Norfolk and Norwich University Hospital
Healthcare Trust. The participants were 46 women, 2 years or more
post diagnosis of breast cancer (range 2–20 years), aged 30–85 years,
with no active recurrent disease. The women were undergoing follow-up
in hospital or in general practice, or no follow-up.
Six focus group meetings were held initially, transcribed and themes
derived using N*Vivo software and constant comparison. Individual
interviews were then carried out to explore the themes, and to widen
the range of participants.
Results  Themes identified fell into two categories: discharge from
hospital care, and information. Themes related to the former included
initial disease experience, whether the cancer was detected mammo-
graphically or self-detected, uncertainty about recurrence, ‘expert’
care’, and continuity of care. Themes related to information included
follow-up protocols, breast care nurses, tamoxifen, mammography,
lymphoedema, and the role of support groups.
Conclusions Women wished to participate in decisions on follow-up.
A small group of women preferred hospital follow-up long term. Most
others would value a final hospital appointment generating a plan for
further follow-up. They would then be content to be discharged to GP
care, preferably with telephone access to a breast care nurse. A few
women were confident to be discharged fully to self-examination and
mammography with no formal follow-up. The breast care nurses were a
popular choice to provide ‘expert’ information at every stage of the
process, and were perceived as easily accessible. This study supports
increasing the role of breast care nurses in the community after
discharge from hospital care.
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Background  This study explored the psychosocial impact of being
diagnosed and treated for ductal carcinoma in situ (DCIS), with the aim
to improve the current knowledge and understanding of DCIS from the
patient’s perspective. DCIS is a preinvasive breast condition increasingly
detected by mammogram screening and has an uncertain natural
history (some DCIS cells may develop into invasive cancer, but there is
no marker to determine which DCIS cells will). Although DCIS is not an
invasive condition, many women undergo extensive surgery (including
mastectomy); therefore, this is a paradoxical situation – these women
are reassured that it is noninvasive, caught early and not life-
threatening, but they are offered similar treatment as women with
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findings of an exploratory qualitative study.
Methods In-depth semistructured interviews with 16 women previously
diagnosed with DCIS explored their experience. Thematic analysis
highlighted the important issues from the women’s own perspective.
Results  This study identified seven themes, which included two
subthemes relating to appearance that are presented here. The
paradox of DCIS and concerns about appearance were clearly evident
in several participants.
Conclusion  The results emphasise that women may have post-
treatment concerns and appearance issues following surgery for DCIS;
these women may require specific support and advice in order to
adjust for and accept the impact that the treatment may have on their
appearance and feelings following surgery. Further research is needed
to explore this area. The research team plans to address this by
following a group of DCIS patients prospectively in order to identify
how women’s feelings and concerns (including appearance) change
during the diagnosis and treatment for DCIS.
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Background  Counselling, risk assessment and surveillance are
provided for women with a significant family history of breast cancer
through a network of clinical centres across the United Kingdom.
Before 2004, the recommended minimum ‘threshold’ for significant
familial risk was set by a number of guidelines issued, which broadly
required one first-degree relative diagnosed with breast cancer before
age 40 or two close relatives both diagnosed before age 60. In 2004,
NICE issued detailed guidelines in which the age requirement for two
affected relatives was removed. However, it is widely recognised that
the evidence base for any specific minimum threshold is limited and
that there is a need for empirical studies to validate current and future
recommendations. That is the object of the present study.
Methods Records of the four Scottish Breast Cancer Family clinics
were scrutinised for the period January 1994–December 2003 to
identify any women referred but discharged because the level of
familial risk was judged to fall below the (pre-NICE) threshold. From
dates of birth and dates of discharge, the number of women-years of
observation (to December 2003) within each 5-year age group
(35–39 years, 40–44 years, and so on) was calculated. With
permission from the Privacy Committee, the list was then checked
against Scottish Cancer Registry records and any breast cancers
recorded were rechecked from hospital notes. Expected cancer rates
for an age-matched Scottish population were derived from Cancer
Registry Statistics.
Results A total of 2,074 ‘low risk’ women were identified, giving over
8,000 woman-years of observation. Twenty-eight invasive breast cancers
were recorded while 14.4 would have been expected (relative risk = 1.9
assuming complete ascertainment). A further eight invasive breast
cancers have been recorded since 2003 (records incomplete). One-third
of the cancers were in women who would have met the new NICE
criteria for surveillance, whereas only some 10% of the total cohort had
‘NICE moderate’ family histories. The great majority of the cancers
occurred in women between age 45 and 56. For them the relative risk
approached 2 even when ‘NICE moderate’ women were excluded.
Conclusion The new NICE family history guidelines are more accurate
than previous ones in identifying women who should be included in
breast surveillance programmes, but consideration should be given to
making some provision particularly for women between age 45 and 56
with ‘limited’ family histories of breast cancer. The cohort we have
identified should continue to be followed up since cancers are
continuing to accrue and each year provides a further 2,000+ woman-
years of observation.
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Background The objective was to establish a murine model to study
the role of macrophages in the initiation of angiogenesis by human
breast tumour spheroids in vivo. Despite the increasing body of
evidence, both experimental and clinical, implicating macrophages in
breast tumour angiogenesis, there have been no previous in vivo
studies demonstrating proangiogenic tumour activity.
Methods  Human breast tumour spheroids (600 µm) were infiltrated
with human monocytes in vitro, allowed to differentiate into macro-
phages, coated with alginate to isolate from the host (murine) cells and
implanted into dorsal skin-fold chambers on nude mice. The resultant
angiogenesis surrounding the spheroids infiltrated with human
macrophages prior to implantation was quantified using image analysis
(Angiosys), and compared with that induced by spheroids consisting of
tumour cells alone.
Results The presence of macrophages resulted in at least a threefold
upregulation in the release of vascular endothelial growth factor
(VEGF)  in vitro when compared with spheroids composed only of
tumour cells. A homogeneous distribution of macrophages surrounding
the hypoxic centre was observed in the majority of spheroid sections
assessed. The angiogenic response measured around the spheroids 3
days after in vivo implantation was significantly greater in the spheroids
infiltrated with macrophages; the number of vessels increased
(macrophages vs no macrophages, 34 ± 1.9 vs 26 ± 2.5, P < 0.01),
and were shorter in length (macrophages vs no macrophages,
116 ± 4.92 vs 136 ± 6.52, P < 0.008) with an increased number of
junctions (macrophages vs no macrophages, 14 ± 0.93 vs 11 ± 1.25,
P < 0.025), all parameters indicative of new vessel formation. By day 7
no significant differences were seen. Viable human but no murine
macrophages were identified in the tumour spheroids at the end of the
study, using immunohistochemistry.
Conclusions This is the first in vivo study to demonstrate that
macrophages modulate breast tumour angiogenesis, in the early
stages of development, with an increased number of vessels and
branches.
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Background  In many cell types, transforming growth factor beta
(TGFβ) results in a growth inhibitory signal, which is mediated by
transducers of the Smad family. In tumour cells, however, TGFβ-
dependent antiproliferative control is lost and cells acquire the ability to
replicate in TGFβ-rich environments. Furthermore, molecular and
clinical evidence points to a role for TGFβ signalling in cancer
progression and metastasis; however, it is unclear at which points of
the metastatic process TGFβ signalling occurs and whether it is
necessary and/or sufficient to elicit cancer cell motility.
Methods To address these questions, MTln3E rat breast cancer cells
were used as a relevant model system. When injected into the
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mammary fat pad of nude mice, these cells form a primary tumour from
which motile cells will depart to form metastasis in the lymph nodes and
the lungs. To gain insight into TGFβ signalling in vivo, MTln3E cells
were engineered to express GFPSmad2. This allowed monitoring
Smad-dependent TGFβ signalling in vivo by imaging the primary tumour
and in lymph-node metastasis using multiphoton confocal microscopy.
Results  The results indicate that TGFβ signalling, measured by
cytoplasmic to nuclear translocation of GFPSmad2, does not occur
ubiquitously within the primary tumour. On the contrary, TGFβ
signalling appears most prominent in movement-rich areas. Within
these areas, all the cells that have acquired a motile phenotype display
active TGFβ signalling. Furthermore, none of the motile cells display
nuclear exclusion of GFPSmad2.
Conclusions Together these data suggest that TGFβ signalling may
be required in metastatic cells, possibly to enable acquisition of the
motility phenotype. However, as nuclear localisation of GFPSmad2 is
observed also in nonmotile cells, TGFβ signalling alone may not be
sufficient to elicit cell motility in primary tumour cells.